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Abstract 
Background: Infertility affects one in six couples (1) and hence is an important health issue, which can have significant medical, psychological and financial implications for couples.  In vitro fertilization (IVF) is an effective treatment for infertility. However, one of the major complications that can arise from IVF treatment is ovarian hyperstimulation syndrome (OHSS). OHSS is predominantly related to the mode of triggering oocyte maturation during IVF treatment. It has been previously reported that a single dose of kisspeptin results in an LH-surge of ~12-14hrs duration, which safely triggers oocyte maturation in women at high risk of OHSS, but has yet to be directly compared with other triggers. I hypothesised that increasing the duration of LH-exposure by administering a second dose of kisspeptin could further optimise oocyte maturation without increasing the incidence of OHSS.  
Ovarian volume and ascitic fluid are commonly used to categorise the severity of OHSS in diagnostic guidelines. I also aimed to address if ovarian volume at early OHSS screening (day 2-10 following oocyte retrieval) altered when using different triggers of oocyte maturation (hCG, GnRH agonist or kisspeptin). 
 
Methods: This was a phase-2 single-blinded randomised placebo-controlled trial of 62 women at high risk of OHSS undergoing IVF treatment at Hammersmith Hospital, 
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London, UK. Following a recombinant FSH/GnRH-antagonist superovulation protocol, all patients (n=62) received a subcutaneous injection of kisspeptin-54 (9.6nmol/kg) 36hrs prior to oocyte retrieval. Patients were then randomised 1:1 to receive either a second dose of kisspeptin (D; Double, n=31), or saline (S; Single, n=31) 10hrs thereafter. Oocytes were retrieved transvaginally 36h after kisspeptin injection, assessed for maturation (primary outcome), and fertilised by intracytoplasmic sperm injection with subsequent transfer of one or two embryos.  
A second retrospective study was conducted  assessing all women at high risk of OHSS (antral follicle count ≥23), aged <35yrs, BMI <30 kg/m2 with both ovaries intact, for  sonographic signs and for OHSS symptoms during early OHSS screening (2-10 days following oocyte retrieval) at Hammersmith Hospital, London, UK (2013-2016). 
Ovarian volume on ultrasound, ascitic volume and OHSS symptoms were determined when patients were triggered with (hCG) (n=44), GnRH agonist (GnRHa) (n=94) or kisspeptin (n=115) at time of early OHSS screening.  
 
Results A second injection of kisspeptin significantly induced further LH-secretion at 4hrs and 10hrs after injection compared to saline (P<0.0001). A higher proportion of patients achieved satisfactory oocyte yield following a second dose of kisspeptin (S:45.2%, D:71.0%; absolute difference +25.8%, CI 2.1-49.5%, P=0.042). There was no difference in the frequency of OHSS between the two groups. The mean 
7 
 
implantation rates following a double dose were higher (37.1±48.2%) when compared to a single dose (23.3±43%) of kisspeptin. 
Average mean ovarian volume (MOV) following hCG trigger was 172mls ±89mls, 88 ±60mls after GnRHa trigger and 53±37mls following kisspeptin trigger (p<0.0001). The mean change in ovarian volume from baseline to OHSS screening for hCG was 166±87mls (25-fold), 75±56mls (10-fold) with GnRHa and 41±35mls (6-fold) following kisspeptin (p<0.0001). OHSS symptoms were reported most frequently following  hCG and least with kisspeptin. 
Conclusion Administering a second dose of kisspeptin safely improves oocyte yield in women undergoing IVF treatment. Kisspeptin may thus present a safer alternative than GnRHa or hCG triggering in patient at high risk of OHSS. 
 
 
Trial registration: ClinicalTrials.gov NCT01667406  
Funding: Medical Research Council, Wellcome Trust & National Institute of Health Research.        
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Infertility 
Infertility is defined by the National Institute for Health and Clinical Excellence (NICE) as the inability of a couple to conceive after two years of regular unprotected intercourse. They also estimate that infertility affects one in seven couples in the UK making it an important health issue that can have significant implications medically, psychologically and financially on those finding it difficult to conceive. The Human Fertilisation and Embryology Authority (HFEA) has reported that after pregnancy, infertility is the most common reason for women aged 20–45 to seek medical advice in primary care. 
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In vitro fertilisation 
The birth of Louise Brown in 1978, the first baby born via in vitro fertilisation (IVF), revolutionised assisted conception and IVF has become the mainstay of fertility treatment worldwide. In the early stages of IVF, single oocytes were collected from natural cycles. However, the development of ovarian stimulation regimens promoting multifollicular growth, timed oocyte maturation, luteal phase support and the improvement of embryo culture conditions have had a radically positive effect on the success rates of treatment. IVF is now used routinely to treat infertility associated with a variety of conditions such as anovulation, tubal blockage, male infertility, endometriosis and also where no cause is found.       
Current IVF protocols 
A cycle of IVF aims to mimic a normal menstrual cycle with the exception of inducing multifollicular development. There are several distinct steps by how this is achieved (Figure1):- 
1. FSH stimulation Exogenous FSH is administered to the patients to stimulate the ovaries in order that multiple follicles containing oocytes develop simultaneously.   
2. Prevention of premature ovulation A premature surge of luteinising hormone (LH) could lead to premature ovulation and to a decrease in the number of oocytes retrieved. The use of 
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GnRH analogues and antagonists during the ovarian stimulation phase can prevent the LH surge through reversible blockade of the pituitary GnRH receptors.   
3. Triggering of oocyte maturation In order for oocytes to become mature and gain the competence for fertilisation by sperm, LH exposure is required. This can be achieved through the bolus administration of pharmacological agents such as hCG, which simulates the effects of the natural mid-cycle LH surge.   
4. Oocyte retrieval   The oocytes are usually retrieved transvaginally. The surgeon passes a needle through the vaginal wall under ultrasound guidance and aspirates the follicular fluid to retrieve the egg.  
 
5. Embryogenesis The collected oocytes are then placed adjacent to a high concentration of sperm in laboratory petri dish for in vitro fertilisation (IVF). Alternatively the embryologist may perform a procedure called intracytoplasmic sperm injection (ICSI), during which a single spermatozoon is injected directly into the oocyte for fertilisation.   
6. Luteal phase support After the embryos have been replaced in the uterus, the patients are given exogenous progestogens to enhance the luteal phase and promote decidualisation of the endometrium and implantation of an embryo.     
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LH  LH 
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Figure 1:Phases of IVF treatment: 1) FSH is administered to the patients to stimulate simultaneous development of multiple follicles in the ovaries 2) Prevention of premature ovulation is achieved via administration of GnRH analogues and antagonists during the ovarian stimulation phase through reversible blockade of the pituitary GnRH receptors 3) Follicles undergo maturation via administration of triggers such as hCG, which simulates the effects of the natural mid-cycle LH surge 4) The collected oocytes are placed in a high concentration of sperm for in vitro fertilisation (IVF) or fertilised by injection of a single spermatozoon is directly into the oocyte during a process known as intracytoplasmic sperm injection (ICSI). 
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1. FSH stimulation for folliculogenesis 
This initial phase of treatment is aimed at promoting multifollicular growth within the ovaries. This is achieved by administration of exogenous follicle-stimulating hormone (FSH) which can be either in the recombinant form (rFSH) or human menopausal gonadotrophins (hMG) which are manufactured from the urine of menopausal women. The main distinction between the two preparations is that hMG has both FSH and luteinising hormone (LH) activity whereas rFSH exerts FSH activity alone (2-4)  
2. Prevention of premature LH surge 
Ovarian stimulation protocols were developed in order to induce the growth of multiple follicles during the initial phase of IVF treatment. With higher numbers of eggs being collected and subsequently more embryos being created, the success rate of treatment has dramatically increased (5-8). During the spontaneous menstrual cycle, the mean follicular diameter reaches an average of 20 mm (range 18-26 mm) at the beginning of the LH surge ((9-11). However, during controlled ovarian stimulation (COH) for IVF the occurrence of an endogenous LH surge has been observed in approximately 13% of cycles despite the largest follicle having a mean diameter of less than 16 mm (12). Premature luteinisation, referring to a rise in serum progesterone prior administration of the oocyte maturation trigger, can be associated with adverse effects on the mean number of retrieved oocytes, the number of recovered mature oocytes and embryo quality when compared to a non- prematurely luteinized patient cohort (13, 14). The clinical pregnancy rate has also shown to be higher in non-prematurely luteinized patients (15, 16).   
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(i) GnRHa long protocol 
 The use of gonadotrophin releasing hormone agonists (GnRHa) has allowed for prevention of a premature LH surge via reversibly blocking pituitary gonadotrophin secretion. GnRHa bind to their pituitary receptors and lead to an 
initial stimulatory release of FSH and LH, also termed the ‘flare’ effect. After more prolonged administration, the GnRHa/receptor complex is internalised into the gonadotroph cell. This desensitisation of the pituitary gland usually occurs after at least 14 days of GnRHa administration. Functional recovery time of the GnRHa receptor after cessation of GnRHa administration is variable, which has implications for the luteal phase hormonal profile (17, 18).   Two distinct GnRHa protocols exist: one where the GnRHa agonist is commenced in the mid-luteal phase (day 21 of a 28 day menstrual cycle), and the other where it is commenced in the follicular phase on day 2. The GnRHa agonist is administered for two weeks whereupon pituitary suppression is confirmed via surrogate pelvic ultrasound markers. Once this is confirmed, concurrent administration of GnRHa and gonadotrophins are continued until at least 3 follicles reach a mean diameter of 18mm. It is at this stage that a bolus injection of human chorionic gonadotrophin (hCG) is administered to induce oocyte maturation prior to ooctye recovery. The clinical pregnancy rate is similar between the two protocols (19). However, one study reported a higher incidence of functional ovarian cysts in the follicular phase long protocol (20) which has the potential of disrupting the planning and progress of an IVF cycle. 
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(ii) GnRH antagonist short protocol  Although GnRH agonists have played an important role in reducing the incidence of premature LH surges their use is not without certain disadvantages. The long protocol needs 2–3 weeks for desensitisation  to occur and has relatively high costs due to increased requirement of gonadotrophin injections and increased need for hormonal and ultrasonographic measurements (21). Oestrogen deprivation symptoms such hot flushes, sleep disturbances and headaches can be markedly unpleasant for patients and are frequently observed in the pre-stimulation phase of a long protocol. 
GnRH antagonists have emerged as an alternative in preventing premature LH surges. In comparison to the GnRH agonists, the pharmacological mechanism by which GnRH antagonists suppress the release of gonadotrophins is completely different. GnRH agonists act through chronic administration causing down-regulation of GnRH receptors and desensitisation of the gonadotrophic cells. In contrast GnRH antagonists bind competitively to the GnRH receptors and thereby prevent the endogenous GnRH from exerting its stimulatory effects on the pituitary cells. This competitive blockade of the receptor leads to an immediate arrest of gonadotrophin secretion (22).  
The application of GnRH antagonists for ovulation induction in assisted conception has been shown to result in reduced duration of GnRH analogue treatment and reduce the amount of gonadotrophin needed for stimulation (23).  
Due to the mode of action of the GnRH antagonist, the pituitary remains responsive to GnRHa with GnRH antagonist co-treatment in standard doses (24, 25).  As an 
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alternative to hCG, GnRHa have been used to trigger the endogenous release of LH and FSH resembling the physiological mid-cycle surge of gonadotrophins (26). GnRHa have also been shown to be as efficacious as hCG for induction of ovulation (27-29).  hCG and LH share the same alpha subunit and 81% of the amino acid residues of their beta subunit; hence they bind to the same receptor (30). The half-life of hCG, however, is 24 hours (31) whereas the half-life of LH is 60 minutes (32). A GnRH agonist-induced LH surge has been shown to effectively stimulate ovulation and final oocyte maturation (27, 28).  There are two variations of the GnRH antagonist protocol: namely the fixed and flexible. During the fixed protocol the GnRH antagonist (Cetrotide or Ganirelix) is administered from day six of controlled ovarian stimulation onwards (33). In the flexible protocol administration of the GnRH antagonist is withheld until the lead follicle reaches a mean diameter of at least 14mm.   A meta-analysis comparing the fixed and flexible GnRH antagonist protocols demonstrated no statistically significant difference in pregnancy rates, although there appeared to be a trend towards higher pregnancy rates when the fixed protocol was used (34). However, the flexible protocol was associated with a decrease in the number of doses of GnRH antagonist required and the total amount of gonadotrophins used.  
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FSH is traditionally commenced on day 2 of the menstrual cycle during a GnRH antagonist protocol and therefore the onset of menses was normally a prerequisite. However more recently, with the development of emergency fertility preservation ovarian stimulation protocols prior to chemotherapy for cancer, the antagonist protocol can also be started in the luteal phase which is termed a ‘random start’. Studies have shown that both late follicular phase and luteal phase start antagonist ovarian stimulation protocols were as effective as the conventional early follicular phase start. The number of total and mature oocytes retrieved, oocyte maturity rate, mature oocyte yield, and fertilisation rates were similar across protocols (35).  Early meta-analyses comparing the use of GnRHa ovulation induction with the antagonist protocol demonstrated a 5% reduction in clinical pregnancy rates (36). These findings were also corroborated by Griesenger et al (2005) with the analysis of a large German national IVF database and, as a consequence, the antagonist protocol became the second-line choice for a significant numbers of clinicians (37). However, the most recent meta-analysis has failed to identify any significant difference in live birth rates between the two protocols (38).    
3. Triggering of oocyte maturation 
(i) hCG trigger  Ovulation in a natural cycle is initiated and perpetuated by a mid-cycle surge of LH released by the pituitary gland. The LH surge acts to induce final oocyte maturation 
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whereby the first meiotic division is completed with extrusion of the polar body and it is then arrested in prophase of the second meiotic division until fertilisation.  hCG shares the same alpha subunit and 81% of the amino acids of the beta subunit of LH and hence binds to the same receptor (30). Initially high doses of urinary hCG (5000-10,000iu) were administered to women to successfully mimic the physiological LH surge and induce oocyte maturation. More recently the use of recombinant hCG has become widespread following on from the randomised controlled trial (RCT) conducted by Papanikolaou et al (2010) comparing 250 μg recombinant hCG versus 10,000iu urinary hCG. This study concluded the pregnancy rate was significantly higher using recombinant hCG (40). 
hCG also has a stimulating action on the development and function of the corpus luteum; namely a luteotrophic effect, that is more potent owing to its longer half-life compared to the endogenous LH surge and as such hCG can still be detected in the serum 10 days after the preovulatory bolus injection (27, 31, 41).  In contrast the physiological LH surge in a normal menstrual cycle lasts 48 hours. Consequently, continued support of the corpus luteum by hCG elicits supraphysiological luteal phase steroid concentrations. In the context of an exaggerated  ovarian response secondary to stimulation (i.e. a large number late follicular phase follicles and very high oestradiol levels), both recombinant and urinary hCG have clearly been associated with an increased risk of OHSS (42-44).The induction and stimulation of multiple corpora lutea may represent a key phenomenon in this regard. Consequently, the investigation and development of alternative triggering agents continues.  
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(ii) GnRH agonist trigger  As previously outlined, GnRHa initially induce a surge in gonadotrophin production 
termed the ‘flare’ effect. During the long agonist protocol, it is its continued administration that leads to downregulation of its receptor and desensitisation of the pituitary.  With the advent of the GnRH antagonist protocol, where the GnRH receptor is not unresponsive rather competitively inhibited, GnRHa can be used as an alternative to hCG to induce oocyte maturation. The GnRHa displaces the GnRH antagonist from the pituitary GnRH receptor thereby initiating an endogenous surge of gonadotrophins, namely LH and FSH.   The gonadotrophin surge generated by administration of  GnRHa differs from a physiogical LH surge that occurs in a normal menstrual cycle. The physiological LH surge has three distinct phases: the ascending, the plateau and the descending. Each of these phase durations are 14, 14 and 20 hours respectively (45). In comparison, the GnRHa-induced LH surge has two phases: the rapid ascending phase lasting approximately 4 hours and the longer descending phase of 20 hours (28).  The shortened duration of the LH surge with a GnRHa trigger significantly reduces the total amount of LH released when compared to a normal menstrual cycle (27, 28). As a result, the GnRHa trigger is associated with a deficient luteal phase steroid profile and subsequently lower pregnancy rates (46, 47). However, despite this, the GnRHa trigger has a much better safety profile with regards to OHSS when compared to hCG (48, 49). Another observed benefit is the retrieval of a larger 
29 
 
proportion of metaphase II (MII) oocytes when compared to hCG (49). This can be in part attributed to the concomitant FSH surge that occurs with the LH surge when GnRHa are administered. Theoretically the concurrent surge in FSH can promote oocyte nuclear maturation, through resumption of the second meiotic division and potentiate the formation of LH receptors in the luteinised granulosa cells, thus supporting the function of multiple corpora lutea (50-53). 
 
4. Transvaginal oocyte retrieval 
Transvaginal ultrasonography-guided oocyte retrieval is performed approximately 36 hours following the ovulation induction trigger injection. The surgeon inserts a single or double lumen needle through the lateral fornix of the vagina into the peritoneal cavity and then into the ovary. Care is taken to avoid injuring adjacent structures. The proximal end of the needle is attached to suction apparatus and after each ovarian follicle is penetrated the follicular fluid is aspirated under suction ranging from 100-150mmHg for single and double lumen respectively. The follicular fluid is then transferred to an embryologist in the adjacent laboratory who then examines the aspirate to identify and quantify the number of oocytes collected. Once all of the accessible follicles are aspirated, the needle is withdrawn from the lateral fornix and the procedure is repeated in the contralateral ovary.  
5. Embryogenesis 
Fertilisation of oocytes by sperm can be achieved in the laboratory via two methods: IVF or IVF with intracytoplasmic sperm injection (ICSI). Conventional IVF involves placement of an oocyte in culture medium containing motile sperm at a 
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concentration of  50–100,000 sperm per millilitre (ml). Fertilisation occurs when a sperm binds to the surface of the extracellular zona pellucida that surrounds the egg. Following zona penetration and fusion with the oocyte plasma membrane, peripherally located cortical granules within the egg exocytose their contents, which modifies the zona matrix such that sperm no longer bind. These events are orchestrated to ensure that a single sperm fertilises a single egg.  
ICSI fertilisation involves oocytes being denuded of cumulus cells using hyaluronidase and subsequently being assessed for maturity. Mature oocytes are identified if extrusion of the first polar body (metaphase II) has occurred. The oocyte is immobilised using a holding pipette; an injection pipette is used to aspirate a single spermatozoon. Immobilisation of the spermatozoon can be achieved by crushing the tail with the injection pipette and aspirating it into the injection needle. The spermatozoon is then passed through the zona pellucida and directly injected into the ooplasm (Figure 2). ICSI is recommended for male factor infertility where there is a reduced sperm count, poor motility or a low number of morphologically normal sperm (<4%). ICSI can also be used in cases where there was low proportion of fertilisation or complete failure of fertilisation with previous IVF. 
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Figure 2: Intracytoplasmic sperm injection (ICSI). The oocyte is held in position by a holding pipette while the micro injector injects the spermatozoon into the ooplasm from 
the opposite position. The polar body is visible at 6 o’clock position. (Image courtesy of IVF Hammersmith, Imperial College Healthcare NHS Trust) 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6. Embryo development 
Oocytes are assessed for fertilisation 16-18 hours after the ICSI procedure. The oocytes are considered fertilised when two pronuclei are identifiable in the ooplasm (2PN stage). The female and male pronuclei contain haploid copies of their respective chromosomes. The 2-PN zygotes then enter the cleavage stage. The resultant embryos enter the four-cell stage on day 2 and the 6-8-cell stage on day 3, and following full compaction of the embryonic cells on day 4 (morula stage) a blastocoele cavity forms on day 5 (Figure 3). The blastocoele separates the embryonic components to the inner cell mass and the trophoectoderm which will subsequently form the foetus and placenta respectively.  Given that the embryonic genome becomes fully activated at the 8-cell stage, preference is given to using embryos that have undergone this transition from the maternal to the embryonic genome (Braude et al, 1988). Embryo selection following IVF for return to the uterus for implantation depends on a grading system, which is based on morphological criteria (Table 1).   
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Figure 3: Timeline of the fertilised 2PN zygote entering the cleavage stage containing 4 blastomeres on day 2, 6-8 blastomeres on day 3, blastomeres compacting into a morula on day 4, and reaching blastocyst at day 5. On day 6 then embryo hatches out to the zona pellucida. Images taken from: http://yaolab.stanford.edu/images/Slide7_ Retrieved on 30/07/12) 
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Table 1: Grading system for day 2/3 embryos (blastomere) and day 5/6 embryos (blastocyst) (54). 
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A significant increase in biochemical pregnancy (confirmed by the presence of a positive pregnancy test) (OR 1.45, 95% CI 1.03–2.04) and clinical pregnancy rates (defined by the presence of an active foetal heartbeat at the 6th gestational week ultrasound) (OR 1.63, 95% CI 1.12–2.35) was observed after single blastocyst transfer compared with transfer of a single cleavage stage (day 3) embryo in patients aged less than 36 years old (55, 56). Similar pregnancy outcomes have been reported following the transfer of a single versus double blastocyst transfer (57, 58). However, twin pregnancies have been reported to be significantly higher following double embryo transfer (3.5% in single embryo transfer versus 37.5% with double P < 0.05) (58). 
 
7. Luteal phase support. 
The luteal phase is defined as the period between ovulation and either the establishment of a pregnancy or the onset of menses two weeks later (59). During normo-ovulatory cycles, the corpus luteum remains dependent on support from the pituitary gonadotrophins throughout the luteal phase. The spontaneous LH surge results in luteinisation of theca and granulosa cells, a switch from the predominant production of oestrogen to progesterone, the induction of the final stages of oocyte maturation. The luteinised granulosa cells represent the most important progesterone-producing cells of the corpus luteum. LH is the principal trophic hormone for the corpus luteum (60, 61) and decreasing LH concentration induces the structural and functional degradation of the corpus luteum termed luteolysis . (62). Luteolysis can also be induced by the luteal phase administration of a GnRH agonist (62, 63) or an antagonist (64). Continued support of the corpus 
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luteum by LH is critical and luteal regression becomes non- reversible when endogenous LH is lacking beyond 72 hours (65, 66). The pulsatile release of LH is closely controlled by oestradiol and progesterone feedback loops (67). Adequate corpus luteum function is necessary for conception to occur. Luteal regression during the normal menstrual cycle is caused by reduced responsiveness of the aging corpus luteum to LH (68), which can be overcome by administering increasing doses of LH (69) or hCG (either administered exogenously, or as occurs during pregnancy).  
The luteal phase of stimulated IVF cycles is abnormal (70, 71) and is likely to be related to the supraphysiological levels of steroids secreted by a high number of corpora lutea during the early luteal phase. This directly inhibits the release of LH via negative feedback actions at the hypothalamic-pituitary level (72). 
The profound suppression of pituitary gonadotrophin release after cessation of GnRHa is well established (73, 74). Earlier cessation of GnRHa administration during follicular phase stimulation aimed at enabling recovery from pituitary desensitisation was not shown to be successful (41, 75). Due the known rapid recovery of pituitary gonadotrophin release following cessation of GnRH antagonists (76), researchers speculated that GnRH antagonist co-treatment could be applied to IVF without disrupting the luteal phase steroid profile. Although initial studies were inconclusive (77, 78), a recent study focusing on the non-supplemented luteal phase endocrinology following GnRH antagonist co-treatment clearly demonstrated abnormal steroid profiles, along with extremely low LH concentrations, profoundly reduced luteal phase lengths and significantly compromised chances of pregnancy (79).   
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Progesterone induces secretory transformation of the endometrium in the luteal phase (80). By inducing this change following oestrogen priming in the follicular phase, progesterone improves endometrial receptivity (81). During this period of receptivity, the endometrial epithelium develops a functional and transient ovarian steroid-dependent status that facilitates embryo attachment (82). Decreased endometrial receptivity is considered largely responsible for the low implantation rates in IVF (83). 
Csapo et al. (1972, 1973) highlighted the importance of progesterone during the first weeks of a pregnancy. The removal of the corpus luteum prior to 7 weeks of gestation led to miscarriage in their initial study (84). However, they found that the pregnancy could be maintained even after removal of the corpus luteum if exogenous progesterone was administered (85). Therefore, luteal phase supplementation with hCG or progesterone following IVF has become ubiquitous as it results in an increased pregnancy rate (PR) (93). The use of progesterone in those with a history of recurrent miscarriage following spontaneous pregnancy remains contentious. A Cochrane review demonstrated a significant improvement in miscarriage rates in this subgroup of women (205) whereas a recent multicentre RCT did not (86).  In 1985, Leeton et al. first demonstrated the extension of the luteal phase of stimulated IVF cycles by administering 50 mg intramuscular (IM) progesterone (87). Subsequent trials have yielded conflicting results. In an open label study evaluating 1184 women receiving either vaginal and IM progesterone for luteal phase support (LPS), the clinical and ongoing PRwere comparable (35.1 versus 
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35.2%, respectively) and  (30.2 and 33.6%, respectively)(88). However, meta-analysis of 5 studies comparing IM administration of progesterone with vaginal application concluded that clinical PR and delivery rate were significantly higher when IM progesterone was used (89).   However, this route of administration is often associated with a number of side effects, including painful injections and rash (90) causing difficulties with patient tolerance and compliance (91). In addition to this, injections of progesterone in oil can also cause inflammatory reactions and abscesses (92). Vaginal administration of progesterone is a viable alternative to the IM injections of progesterone if the side effects of IM injections are proving too severe.   
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Ovarian Hyperstimulation Syndrome (OHSS) 
One of the major complications of IVF treatment is a condition known as OHSS. It is a systemic disease that can affect the cardiovascular, hepatorenal and central nervous systems leading to significant morbidity and even mortality. The severity of OHSS can vary with mild forms accounting for up to 33% of all IVF cycles. Severe OHSS is reported to occur between 3-8% of IVF cycles (194)  
Risk Factors Certain patient and cycle characteristics increase the risk of OHSS; women with a previous history of OHSS, polycystic ovary syndrome (94) increased antral follicle count (AFC) or high levels of anti-Mu llerian hormone (AMH) (95, 96), elevated serum oestradiol during ovarian stimulation (98) and high doses of exogenous FSH during ovarian stimulation (99).  Some studies have also noted that mean body mass index (BMI) (97) and age (94, 97) were lower in women that developed OHSS compared to those that did not.  
The risk of OHSS is also related to the number of developing follicles during the follicular phase of ovarian stimulation (42) and the number of retrieved oocytes at the end of the cycle (100). The risk also appears to increase when hCG is administered to induce oocyte maturation. OHSS manifestation becomes less likely when progesterone-based luteal phase support is used instead of hCG (101).  
Clinical features Cardinal symptoms of OHSS are abdominal bloating, pain and nausea or vomiting related to ascites and large ovarian volumes. As the disease progresses more 
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serious sequelae can manifest as outlined below. The Royal College of Obstetricians and Gynaecologists (RCOG) has employed the following classification for OHSS (Table 2).  
OHSS can also be classified as early or late onset. The cause of early onset OHSS is typically due to the use of hCG to induce oocyte maturation prior to retrieval. Although hCG and LH share the same alpha subunit, the circulating half-life of hCG is much longer than that of LH; circulating for up to 7 days post administration (31) compared to the physiological LH surge lasting approximately 48 hours (102). As a consequence hCG can excessively stimulate the ovary, driving the pathophysiology of this condition. The hallmark of OHSS is an increase in capillary permeability resulting in a fluid shift from the intravascular space to third space compartments (103, 104). Vascular endothelial growth factor (VEGF), has emerged as one of the factors most likely involved in the pathophysiology of OHSS (105). VEGF is an angiogenic cytokine that is a potent stimulator of the vascular endothelium and appears to play an integral role in follicular growth, corpus luteum function, and ovarian angiogenesis. Recent studies also indicate that hCG increases VEGF expression in human granulosa cells and raises serum VEGF concentrations (106, 107). VEGF has been implicated as it known to increase vascular permeability to high molecular weight proteins promoting capillary leakage (108). 
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Table 2: RCOG classification of severity of OHSS 
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Management of OHSS The management of patients with mild or moderate OHSS can be on an outpatient basis. These patients mainly require supportive therapy, in the form of analgesia and antiemetics, and monitoring for progression of disease severity. Clinical review of symptoms and ultrasound examination to measure ovarian size and to determine the presence ascites is useful in assessing the severity of OHSS. Recommended laboratory investigations include haemoglobin, haematocrit, liver function tests, serum creatinine, urea and electrolytes. 
Women are encouraged to drink to thirst to reduce the risk of haemoconcentration and physical activity should be maintained as reduced mobility may increase the risk of thrombosis. Women should continue luteal supoort with progesterone and not hCG. Patients are advised to avoid sexual intercourse and strenuous exercise as it may worsen pain and may increase the risk of ovarian torsion. Hospitalisation is indicated in cases of severe or critical OHSS (Table 2).  
Prevention of OHSS  Various strategies have been adopted in order to reduce the risk of the development of OHSS. Administering the lowest effective dose of FSH in women with polycystic ovarian syndrome (PCOS) has been shown to reduce the incidence (109). Pre-treatment with metformin prior to commencing IVF also has a protective effect in the same patient cohort (110). Similarly, dopamine agonists have been shown to reduce the incidence of OHSS by binding to VEGFR-2 receptor, reducing its activity and decreasing vascular permeability (111).  
The most effective development in combatting the incidence of OHSS, especially in 
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the high-risk population, has been the introduction of the GnRH antagonist protocol. This protocol allows the use of a GnRHa instead of hCG to induce oocyte maturation. Administration of a single dose of GnRH agonist, after co-treatment with GnRH antagonist, induces an endogenous rise of both FSH and LH which results in the induction of the final stages of oocyte maturation (112). The shorter half-life of the endogenous LH surge and the subsequent pituitary suppression due to GnRH receptor desensitisation, leads to a withdrawal of LH support for the corpora lutea that may lead to early luteolysis and possible abolition of the secretion of the vasoactive peptides responsible for causing OHSS (113). However, the abnormal luteal phase steroid profile after GnRHa trigger (79) has been shown to be associated with impaired implantation and lower on-going pregnancy rates compared to hCG (46, 114).  
As a result, there remains a need to identify novel oocyte maturation triggers that have an effective safety profile in terms of reducing the risk of OHSS but that maintain ongoing pregnancy success rates. Kisspeptin is a neuropeptide that has such potential. 
 
Kisspeptin 
The KISS1 gene, encoding for the neuropeptides termed kisspeptins, was first identified in 1996 as a tumour suppressor in malignant melanoma (115) The gene 
was named after the famous chocolate ‘kisses’ produced in the town of its discovery, Hershey (PA, USA). The KISS1 gene is located on chromosome 1q32 consisting of 4 exons where the first two are not translated (116). 
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Kisspeptin and its receptor  
 G protein-coupled receptors (GPR) are the largest category of cell membrane receptors in humans (117). The GPR54 receptor was first described in the rat model (118) and subsequently the human brain (119). The GPR54 gene is located at chromosome 19p13.3 consisting of five exons encoding a protein of 398 amino acids with seven hydrophobic, trans-membrane domains (119). Upon kisspeptin binding to it, the GPR54 receptor activates phospholipase C and subsequently recruits intracellular messengers, such as inositol triphosphate and diacylglycerol. These messengers mediate a biphasic rise of intracellular calcium (120) and protein kinase C activation which execute kisspeptin’s function (119, 121).  
The KISS-1 gene initially encodes for a precursor 145- amino acid peptide, which is subsequently cleaved into a 54-amino acid product called kisspeptin-54 (116). This can be cleaved further to 14,13 and 10-amino acid peptides all sharing a common C-terminal that is responsible for the high affinity binding and activation of the GPR54 receptor (122). 
 
The neuroanatomical distribution and expression of KISS-1/Kiss-1 
 
Kiss-1 mRNA is predominantly expressed in the hypothalamic anteroventral periventricular (AVPV) nucleus and the preoptic periventricular (POPV) nucleus in rodents (123, 124). This differs from humans who have a more scattered distribution of in the preoptic region (125, 126). Furthermore, kisspeptin and GnRH neuronal networks lie in close proximity in the hypothalamus as demonstrated in animal models (127-129) and also in humans (130) suggesting 
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that kisspeptin has direct involvement in GnRH neurosecretion. The physiological role of kisspeptin-regulated GnRH secretion is demonstrated via abolition of kisspeptin-induced GnRH neuron depolarisation by a kisspeptin antagonist (131-133). Kisspeptin acts upstream of GnRH as demonstrated by the prevention of kisspeptin-induced LH release by pretreatment with a GnRH antagonist (123, 134). 
Kisspeptin stimulates GnRH secretion Exogenous administration of kisspeptin was first shown to potently stimulate the hypothalamic-pituitary-gonadal axis in the rat model (135). Intra-cerebroventricular and intravenous administration of kisspeptin-10 to adult male rats, results in a dose-dependent increase in plasma LH, FSH and testosterone. This was also demonstrated in sheep where central administration of kisspeptin intracerebroventricularly produced a dramatic release of GnRH into the cerebrospinal fluid, with a parallel rise in serum LH (127).  
In addition, intravenous infusion of kisspeptin in oophorectomised sheep produced an increase of serum FSH and LH release (136). In the primate, repetitive kisspeptin administration to agonadal prepubertal males, primed with GnRH to enhance pituitary responsiveness, elicited GnRH-dependent LH secretion similar to that of adults (134, 137). Conversely, Clarkson et al (2008) were able to demonstrate the absence of the LH surge in GPR54 knockout mice (138).  
GPR54 is predominantly expressed in the central nervous system (spinal cord, caudate nucleus, substantia nigra, hippocampus, amygdala and thalamus), endocrine organs (pituitary gland and pancreas) and the placenta. The highest expression of the GPR54 receptor is in the pituitary gland and the placenta (122).  
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There is significant overlap between kisspeptin, neurokinin B and dynorphin neurons in the human hypothalamus (130, 140). These neurons expressing all three neuropeptides are termed KNDy neurons (141). KNDy neurons make direct contact with GnRH cell bodies in humans (142). In the murine model dynorphin and NKB act autosynaptically on kisspeptin neurons coordinate the pulsatile release of GnRH into the portal circulation (143). In this study, neurokinin B was found to have a stimulatory effect and dynorphin an inhibitory one on kisspeptin neurons.  The pulsatile release of GnRH leads to the secretion of LH and FSH from the gonadotroph cells in the anterior pituitary gland (124, 131). This observation was consistent with those seen in primates showing the coinciding pulsatile release of kisspeptin and GnRH secretion, as measured in the median eminence of the monkey (144). Furthermore, kisspeptin’s pivotal role in controlling reproductive function is highlighted by the fact that mutations of the GPR54 gene are the cause of hypogonadotrophic hypogonadism and delayed puberty in humans (145, 146); whereas activating mutation of GPR54 results in central precocious puberty (147).  
Kisspeptin-mediated GnRH release is sex steroid dependent. In humans, the infundibulum relays oestrogen and progesterone signalling whereas in the rodent, the AVPV relays positive feedback and the arcuate nucleus negative (148).  
 
Kisspeptin neurons display sexual dimorphism  Interestingly, in rodents, the kisspeptin neurons in the hypothalamus appear to display sexual dimorphism (124). This is particularly true in the AVPV, where there are approximately 25 times more kisspeptin cell bodies in adult females compared 
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with males (149).  Furthermore, kisspeptin neurons located in the AVPV of the rat 
express estrogen receptor α (206, 207), which indicates that these kisspeptin neurons are equipped with the appropriate gonadal steroid hormone receptors required for positive feedback to generate the LH surge. This is important when considering that pre-ovulatory positive steroid feedback is exclusively female. The arcuate nucleus, which controls negative feedback in rodents, does not display this kind of dimorphism (124, 149). More recently, there is also evidence to support the possibility of sexually dimorphic kisspeptin neuron populations in humans. The female hypothalamus has significantly more kisspeptin neurons in the infundibulum and the rostral periventricular area of the third ventricle (RP3V) (130).  Humans also display this dimorphism in their response to kisspeptin. While kisspeptin potently stimulates LH release in men (150) the effect of kisspeptin is far more variable in women depending on which phase of the menstrual cycle kisspeptin is administered (151).  The sexual variation in the neuroanatomical distribution of the kisspeptin pathway, and the differing responses to kisspeptin 
administration, may be a reflection of kisspeptin’s distinct or differing role between the sexes; notably the generation of the preovulatory LH surge which is unique to females.  
Kisspeptin and metabolism   It is well established that reproductive function in humans can be greatly influenced by nutritional status; in that either extreme (being underweight or obese) can have a detrimental effect.  Although GnRH neurons do not express the leptin receptor (Ob-Rb), a significant proportion of kisspeptin neurons in the arcuate nucleus of mice do (152). In this way, kisspeptin may provide the link 
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between nutritional status and reproduction. While the role of leptin in the control of KiSS-1 expression is being investigated, the effects of other metabolic regulators on the KiSS-1 system have remained relatively unexplored so far. In principle, considering the proven reproductive roles of a number of neuropeptides and hormones that are primarily involved in the control of food intake and energy homeostasis (208, 209, 210) a hypothesis that some of these regulators may have also have an impact on KiSS-1 expression or function, in addition to leptin, is a feasible one.  
 Kiss1 mRNA is significantly reduced in obese mice (153) compared with wild-type controls (152). In rats with streptozotocin-induced diabetes, hypothalamic levels of 
Kiss1 mRNA are decreased, which is associated with subsequently reduced levels of circulating gonadotrophins. However, this hypogonadotropic state can be reversed by kisspeptin administration, implying that diminished kisspeptin signaling may explain the reproductive dysfunction that can accompany diabetes (154, 155). Decreased testosterone levels have been observed in obese men with type 2 diabetes with reduced GnRH secretion thought to be the root cause (156). Possible mechanisms for this down-regulation of kisspeptin and subsequent GnRH signalling include increased oestrogen negative feedback in the obese (157) leptin resistance (158) hyperglycaemia and insulin resistance (155, 159). George et al (2013) demonstrated that administration of kisspeptin-10 increased the frequency of LH pulsatility in hypogonadal, type 2 diabetic men (160). 
In the catabolic state, gonadotrophin secretion and expression of Kiss1 mRNA is reduced in rodents and monkeys (161, 162). However, exogenous administration of kisspeptin can restore reproductive function (163).   
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Humans with leptin or leptin receptor mutations demonstrate biochemical hypogonadism (164) and the majority do not have normal pubertal development (165). Leptin deficient mice demonstrate a decrease in the expression of Kiss1 mRNA, which can be partially restored by leptin (152). However, mice with a selective deletion of the leptin receptor from kisspeptin neurons exhibit normal pubertal development and fertility (166) leading to speculation that leptin’s action on kisspeptin neurons is not obligatory for reproductive function. Furthermore, in human studies where leptin mutations were present, a small number of females underwent delayed but spontaneous menses (167, 168) suggesting that even in the absence of leptin activity, some activation of the hypothalamic–pituitary–gonadal axis is possible. Collectively, these findings point to a potentially important role of kisspeptin neurons in regulation of the reproductive axis via metabolic signaling.   
Effects of kisspeptin administration to humans 
 
(i) Healthy volunteers 
 Kisspeptin is a potent stimulator of the reproductive axis in both animal models and in humans. As stated previously, kisspeptin exerts its effects directly on GnRH neurons via its receptor initiating the release of GnRH into the portal circulation. This in turn leads to the secretion of FSH and LH from the anterior pituitary.   Although kisspeptin stimulates the release of gonadotrophins (FSH and LH), its effect on LH secretion is more marked (169, 170). Kisspeptin-54 was first administered into 6 healthy male volunteers in 2005. They received a 90-minute intravenous infusion of kisspeptin at a dose of 4pmol/kg/min for the first 30 minutes and half that dose (2pmol/kg/min) for the remaining 60 minutes. This was 
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associated with a significant rise in serum LH and a less marked rise in FSH and testosterone levels compared to control saline infusion in the same subjects (171) (Figure 4).  The plasma half-life of kisspeptin-54 was calculated to be 27.6 min ± 1.1 min.   
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Figure 4: Mean plasma kisspeptin-IR, LH, FSH, inhibin B and testosterone after 
kisspeptin-54 and control saline infusions. Mean 90-min LH: kisspeptin, 10.8 ± 1.5 vs. saline, 4.2 ± 0.5 U/L; mean 90-min FSH: kisspeptin, 3.9 ± 0.7 vs. saline, 3.2 ± 0.6 U/L mean 180-min testosterone: kisspeptin, 24.9 ± 1.7 vs. saline, 21.7 ± 2.2 nmol/liter (Dhillo et al., 2005) 
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Further studies confirmed the findings of Dhillo et al (2005) by infusing (continually and in bolus-form) kisspeptin-10 into the a cohort of healthy male volunteers (169). Interestingly, despite continuous infusion kisspeptin-10 for 22.5 hours, George et al (2011) demonstrated no tachyphylaxis of the GnRH/LH pathway; indeed LH secretion tended to progressively increase. This may have been due to lower doses of kisspeptin-10 being used and over a shorter duration compared to other studies where tachyphylaxis was observed (172, 173)(Seminara et al., 2006, Jayasena et al., 2009).  
The investigation of the effects of kisspeptin-54 on LH secretion in healthy female volunteers was undertaken by Dhillo et al., 2007.  Every participant was administered subcutaneous boluses of kisspeptin (0.4nmol/kg) and saline in different menstrual cycles. This set of injections was performed once during the follicular, once in the pre-ovulatory and again in the luteal phase of the menstrual cycle. Kisspeptin-54 increased plasma LH compared with saline injection in all phases of the cycle. A varied gonadotrophin secretory response was observed depending on which phase of the menstrual cycle kisspeptin was administered.  In particular, the effect of kisspeptin-54 on LH and FSH in the pre-ovulatory phase was 5-fold greater than in the follicular and luteal phases (151) (Figures 5 and 6). These findings were supported by a further study where ten women in the early follicular phase, three women in the pre-ovulatory phase, and 14 women in the mid-luteal phase received an intravenous bolus of kisspeptin-10 at a dose of 0.24 nmol/kg. LH pulses were observed immediately after kisspeptin administration in all luteal and pre-ovulatory women. However, only half the women in the early follicular phase demonstrated a significant response to kisspeptin (170). 
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Figure 5: Mean ± SEM increase in plasma LH after saline or kisspeptin injection in 
the various phases of the female menstrual cycle. (A:follicular, B:pre-ovulatory, C:luteal, D: all three phases). ***, P<0.001. Mean increase in LH over baseline (IU/liter) ± sem for follicular phase was 0.12 ± 0.17; preovulatory phase, 20.64 ± 2.91 (P < 0.001 vs. follicular phase); luteal phase, 2.17 ± 0.79 (P < 0.01 vs. follicular phase (Dhillo et al, 2007) 
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Figure 6: Mean ± SEM increase in plasma FSH after saline or kisspeptin injection in 
the various phases of the female menstrual cycle (A:follicular, B:pre-ovulatory, C:luteal, D: all three phases). ***, P<0.001. (Dhillo et al, 2007) 
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Of note, kisspeptin-54 also stimulated progesterone release in the luteal phase of the participants. This may be mediated via the secretion of GnRH and subsequently LH (64, 174). However, a more recent study has shown that in rats there is strong intensity of kisspeptin and GPR54 immunoreactivity in the corpus luteum, particularly in the theca and granulosa cells (154). It is therefore plausible that the increase in progesterone after peripheral kisspeptin-54 injection in healthy women represents a direct effect of kisspeptin on the corpus luteum. Recently, kisspeptin expression has been shown to be increased in endometrial stromal cells through decidualisation (175) suggesting a role for kisspeptin in preparing the endometrium for implantation. 
 
(ii) Effect of kisspeptin application in patients with subfertility. 
 
 (a) Women with hypothalamic amenorrhoea 
 Women with hypothalamic amenorrhoea were the first patients in which the therapeutic potential of kisspeptin was explored.  This condition is associated with slow GnRH pulsatility and subsequent decline in FSH and LH secretion. Decreased levels of gonadotrophins lead to low ovarian follicular activity. Ten patients with hypothalamic amenorrhoea were administered subcutaneous injections of kisspeptin-54 at a dose of 6.4nmol/kg twice a day for a period of two weeks. Serum gonadotrophin and oestradiol levels were measured on the day 1 and 14. The results indicated an initial potent rise in serum LH and FSH on the first day of injections (10-fold increase in LH and 2.5 fold in FSH) (173). This response, however, was not sustained and appeared to be significantly reduced by day 14, 
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suggesting that chronic administration of kisspeptin can result in tachyphylaxis (173) (Figure 7). However, the same researchers demonstrated that tachyphylaxis could be avoided by intermittent twice-weekly injections of 6.4 nmol/kg of kisspeptin-54 over an 8 week period (176). Even though an increase in LH and FSH levels into the normal physiological range was observed in both studies, this did not translate into increased ovarian follicular activity (persistent ovarian quiescence on scan and no significant rise in serum oestradiol levels) (173, 176). 
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Figure 7: Effects of kisspeptin-54 and saline injection on the first day (A,B,C) and the 
14th day (D,E,F) to plasma levels of LH, FSH and serum oestradiol. Data are shown at mean ± SEM. *,P<0.05. ***, P<0.001 (Jayasena et al., 2009) 
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(iii) Patients undergoing IVF treatment  
Based on the evidence of kisspeptin’s initial stimulatory effect on GnRH secretion, it was hypothesised that kisspeptin could potentially activate an endogenous LH surge during a cycle of controlled ovarian stimulation and IVF. In addition, whilst hCG mimics LH activity only, kisspeptin has been observed to induce the concomitant release of FSH. Although the mid-cycle LH surge has been predominantly associated with final oocyte maturation and ovulation, FSH has been shown to increase the formation of LH receptors in follicular granulosa cells, promoting nuclear maturation and cumulus expansion (50, 52, 177, 178). Given such findings, kisspeptin was postulated as a potential physiological trigger for oocyte maturation. 
Jayasena et al (2014) administered a single injection of kisspeptin-54 at differing doses (1.6, 3.2, 6.4, or 12.8 nmol/kg) to women undergoing IVF, following standard recombinant follicle-stimulating hormone and GnRH antagonist therapy during an IVF treatment cycle (179). Egg maturation was observed in response to each tested dose of kisspeptin at 36 hours following administration. However, clinically difficult egg retrieval was reported in the 1.6nmol/kg (n=2) and 3.2nmol/kg (n=3) groups and therefore the remaining patients were randomised to either 6.4 or 12.8nmol/kg (n=24 per group). Oocyte yield (the proportion of eggs recovered when compared with the expected number (the number of follicles > 14 mm diameter) and the absolute number of mature eggs appeared to increase in a dose-dependent manner (Table 3).  
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Overnight blood sampling was performed to determine the time profile of hormone release in 20 of the subjects treated with the two highest doses of kisspeptin-54 (6.4 or 12.8 nmol/kg; n = 10/dose). Peak levels of plasma kisspeptin were observed approximately one hour after injection and then fell to preinjection levels by 12 hours following injection (Figure 8). Serum LH levels peaked four to six hours following kisspeptin-54 injection and decreased thereafter. The total length of the LH surge was 12 hours following kisspeptin injection. Similar patterns were observed in FSH and oestradiol secretion but to a lesser extent following kisspeptin-54 injection. In contrast, progesterone levels rose continually during the 12 hours following kisspeptin-54 injection.  
Fertilisation occurred in 92% of patients (defined as at least one fertilised egg) and the rate of embryo transfer was 92%. In addition, 36 of 49 patients who had an embryo transfer did so at the blastocyst stage (day 5 after egg collection). Furthermore, the blastocyst formation rate (defined as the total number of blastocysts divided by the total number of 2PN zygotes formed) in these patients was 49.4% (129 blastocysts from 261 2PN zygotes). The biochemical pregnancy rate was 40%, and the clinical pregnancy rate was 23% (12 of all 53 treated patients). Pregnancy outcomes were as follows: ten women each gave birth to healthy babies (eight women had singleton pregnancies and two women had twin pregnancies); the remaining two women suffered miscarriages (one at nine weeks and the other at 12 weeks gestation). 
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 1.6(n=2) 3.2(n=3) 6.4(n=24) 12.8(n=24) 
M2 4.5(3.5) 4.3(1.5) 7.5 (3.8) 8.8 (4) 
%M2 75 (35) 79 (36) 79 (22) 85 (16) 
Oocyte yield 49 (29) 36 (18) 76 (49) 103 (53) 
        Table 3: Summary of total number of metaphase 2 (M2) oocytes retrieved; percentage of oocytes that were mature; oocyte yield (%) (the proportion of eggs recovered from the number of follicles > 14 mm diameter) per dose (1.6, 3.2, 6.4, or 12.8 nmol/kg) (Jayasena et al., 2014) 
 
 
Kisspeptin-54 dose (nmol/kg): mean(SD) 
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Figure 8: A subgroup of women receiving the two highest doses of kisspeptin-54 (6.4 
or 12.8 nmol/kg; n = 10 per group) at t = 0 minutes underwent overnight 
measurements of circulating kisspeptin-54, LH, FSH, oestradiol, and progesterone at 
t = –30, –15, 0, 30, 60, 90, 120, 150, 180, 240, 360, 480, 600, and 705 minutes. Blue circles show median for 6.4 nmol/kg kisspeptin-54; red triangles show median for 12.8 nmol/kg kisspeptin-54. Vertical lines indicate the interquartile ranges. Conversion factor for serum oestradiol: 1 pmol/l = 0.27 pg/ml; conversion factor for serum progesterone: 1 nmol/l = 0.31 ng/ml (Jayasena et al., 2014) 
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In current practice hCG is the most commonly used hormone to trigger oocyte maturation. hCG acts directly on ovarian LH receptors to stimulate egg maturation. The use of hCG confers an increased risk of OHSS due to prolonged follicular stimulation compared with the endogenous LH surge, and a lack of negative feedback control. In contrast kisspeptin stimulates endogenous GnRH and gonadotrophin release and hence was hypothesized to reduced risk of OHSS.  
In order to test this hypothesis, Abbara et al. (2015) recruited sixty women requiring IVF treatment at high risk of developing OHSS.  Previous work has shown that women with either a serum anti-Müllerian hormone (AMH) greater than 40 pmol/L, or total ovarian antral follicle count (AFC) greater than 23 on ultrasound have a high risk of developing OHSS during IVF treatment (96, 180). Following a standard recombinant FSH/GnRH antagonist protocol, patients were randomly assigned to receive a single injection of kisspeptin-54 to trigger oocyte maturation (3.2 nmol/kg, n = 5; 6.4 nmol/kg, n = 20; 9.6 nmol/kg, n = 15; 12.8 nmol/kg, n = 20). 
Oocyte maturation (≥ 1 mature oocyte) was observed in 95% (57/60) of women who received kisspeptin-54. The highest oocyte yield (121%) was observed following 12.8nmol/kg kisspeptin-54. Oocyte maturation did not occur in three women and another three women suffered failed fertilisation of oocytes following ICSI. A clinical decision to freeze all embryos was made in three women who were deemed at high risk of developing OHSS should they have an embryo transfer. Therefore, embryo formation occurred in 90% (54/60) of women who received kisspeptin-54 and 51 of 60 women had a fresh embryo transfer. 
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At all doses of kisspeptin-54 tested, biochemical pregnancy, clinical pregnancy, and live birth rates per transfer (n = 51) were 63, 53, and 45%, respectively. The highest pregnancy rates were observed following 9.6 nmol/kg kisspeptin-54. Out of 60 participants none developed moderate, severe, or critical OHSS requiring 
medical intervention confirming kisspeptin’s efficacy as a safe trigger of oocyte maturation in those women at high risk of OHSS . The expected rate of moderate or severe OHSS would normally be 10-20% in a high risk population (96). However,  only three women (5%) in this study were diagnosed with mild early OHSS and one (2%) with mild late OHSS (181).  Together this work suggests that kisspeptin is an effective trigger of oocyte maturation and may be a safer trigger than the current 
‘gold’ standard.  The work in this thesis builds on these findings and aims to optimise the protocol for kisspeptin administration to further improve outcomes during IVF treatment and compare the rates of OHSS which occur in women undergoing IVF treatment with different triggers for oocyte maturation (hCG, GnRH, kisspeptin). 
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CHAPTER 2 
Kisspeptin as a novel 
trigger of oocyte 
maturation during IVF 
treatment 
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Introduction: 
The available data, summarised in chapter one, demonstrates that kisspeptin can induce oocyte maturation, embryogenesis and produce live births. It is also associated with low rates of OHSS, even in a high risk population. However, the optimal kisspeptin dosing regime remains unknown. In both IVF studies the oocyte 
yield, defined as the percentage of mature oocyte collected out of all follicles ≥ 14mm, was lower than may have been expected in a significant number of cases. A possible explanation for this is that a single injection of kisspeptin results in an LH surge which lasts for 12 hours (179). In contrast, during a normal menstrual cycle the physiological LH surge lasts a total of 48 hours (102). Given this observation, the question arises as to whether administration of a second dose of kisspeptin would lengthen the duration of the LH surge compared to a single injection of kisspeptin resulting in improved oocyte yield for a higher proportion of patients. The work in this thesis attempts to address this important question.  
 
Hypothesis: 
 Using two doses of kisspeptin to trigger oocyte maturation in IVF treatment will improve oocyte yield compared to administration of a single injection of kisspeptin. 
Aim: 
 To determine if two doses of kisspeptin improve the oocyte yield compared to a single injection in women undergoing IVF treatment. 
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Methods: 
Regulatory approval: 
 
The Hammersmith and Queen Charlotte’s Research Ethics Committee, London, UK, approved this study (reference: 10/H0707/2). The study was carried out in the IVF Unit at Hammersmith Hospital under a license from the UK Human Fertilisation and Embryology Authority. Written informed consent was obtained from all subjects prior to inclusion in the study. Approval of this study as a Clinical Trial of an Investigative Medicinal Product was granted by the Medicines and Healthcare Products Regulatory Agency, UK. The study was registered on the National Institutes of Health Clinical Trials database (NCT01667406). The study was performed in accordance with the Declaration of Helsinki. 
Peptide synthesis 
 Kisspeptin-54 was synthesised and purified by Bachem (Bachem Holding AG, Bubendorf. Switzerland). Sterile vials of Kisspeptin-54 were produced by the Clinalfa brand of Bachem (Bachem Distribution Services GmbH, Weil am Rhein, Germany). Both productions were prepared according to Good Manufacturing Practice (GMP). Vials of freeze-dried kisspeptin-54 were stored at -20OC and reconstituted in 0.5ml of 0·9% saline as previously described (179). 
Sample Size and Power: 
 The sample size was calculated based on oocyte yield data from previous studies using kisspeptin to trigger oocyte maturation (179, 181). Optimal oocyte yield was achieved in 43% of patients using a single kisspeptin injection to trigger oocyte 
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maturation. The oocyte yield was expected to rise to 80% using two kisspeptin injections (based on published data using triggers for oocyte maturation which result in a 24h rise in LH (182). Using Fisher's exact conditional test for two proportions, a sample size of 31 patients per group (±5% drop-out rate) was determined to provide an 80% power using a two-sided α of 0.05 to detect an expected increase in the proportion of patients achieving satisfactory oocyte yield of rising from 43% to 80%. 
 
Study participants: 
 Seventy-six women requiring IVF treatment for infertility at Hammersmith Hospital, London, UK, were screened for participation between October 2014 and August 2015. Eligible patients received one IVF treatment cycle: all treatment costs for this IVF cycle were funded by study participation. The first two inclusion criteria aimed to select women at high risk of OHSS: serum anti-Müllerian hormone 
(AMH) ≥40pmol/L (≥5·6ng/mL) or total antral follicle count (AFC) ≥23; age 18-
34yrs; early follicular phase serum follicle stimulating hormone (FSH) ≤12iU/L; both ovaries intact; body mass index 18-29kg/m2. Exclusion criteria were 
moderate/severe endometriosis and poor response to ≥2 previous cycles of IVF treatment.  
Ten patients were not eligible for inclusion, two patients withdrew consent prior to commencing the study protocol and a further two patients developed conditions requiring additional management during the stimulation phase of treatment beyond the realms of the study protocol (e.g. hydrosalpinx) and were therefore excluded prior to randomisation (Figure 9). In total sixty-two eligible patients 
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underwent a single IVF treatment cycle and were randomised to receive either one (n=31) or two doses (n=31) of kisspeptin to trigger oocyte maturation. 
 
Randomisation and masking: 
 Randomisation was performed using printed lists that were prepared by the trial statistician (L.H.) using SAS 9.3. Sixty-two patients were randomised 1:1 to receive either one or two doses of kisspeptin. All randomised patients were included in the analysis of primary and secondary outcomes. A saline-placebo injection was administered, 10 hours after the first, to participants randomised to a single kisspeptin injection such that participants, embryologists, and IVF clinicians remained blinded to the single or double dose allocation.    
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Figure 9: Recruitment of patients. Inclusion criteria were: serum anti-Müllerian hormone (AMH) ≥40pmol/L  or total antral follicle count (AFC) ≥23(15,16); age 18-34yrs; 
early follicular phase serum follicle stimulating hormone (FSH) ≤12iU/L; both ovaries intact; body mass index 18-29kg/m2. Exclusion criteria were moderate/severe 
endometriosis and poor response to ≥2 previous cycles of IVF treatment. Patients were then randomised to receive a single or double dose of kisspeptin at 9.6nmol/kg. 
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Study outcomes: 
 The primary outcome was the proportion of patients achieving optimal oocyte maturation; this was defined as the proportion of patients achieving an oocyte 
yield (percentage of mature oocytes collected from the number of follicles ≥14mm in diameter on ultrasound scan performed on the morning of first kisspeptin trigger administration) of at least 60%.   Secondary outcomes were the incidence of OHSS; reproductive hormone profiles following kisspeptin administration; and implantation rate (proportion of embryos transferred which implanted at 6weeks gestation. Biochemical pregnancy was defined as a serum hCG level >10mIU/mL 11 days following the embryo transfer procedure and clinical pregnancy was defined as the presence of an intrauterine gestational sac with an active fetal heart pulsation at 6 weeks’ gestation).  
The study protocol is summarised in Figure 10. Participants received ovarian stimulation via daily subcutaneous injections of rFSH (Gonal F 112.5 iU, Merck Serono, Geneva, Switzerland, administered at midday) commencing on day 2 or 3 of their menstrual cycle. Pelvic ultrasound scans were performed five days after commencing rFSH to determine ovarian follicular development and appropriately titrate the dose of rFSH.
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 Figure 10: Study superovulation protocol using either one or two doses of subcutaneous kisspeptin-54 as a trigger to 
induce oocyte maturation. On day 2 of the menstrual cycle, daily subcutaneous recombinant FSH (Gonal F IU) was commenced. After 5 days of recombinant FSH injections, daily GnRH antagonist injections (Cetrotide 0.25mg) were started. Patients were randomised to receive either one, or two injections of kisspeptin-54 10hours apart. Transvaginal ultrasound-directed egg retrieval was carried out 36h following kisspeptin-54 injection. Oocyte yield was calculated. Intracytoplasmic sperm injection was then performed using sperm from the male partner. Intramuscular progesterone and oral oetradiol LPS were given from the day of egg collection to 12 weeks gestation. One or two embryos were be transferred to the uterine cavity 3-5 days following egg collection. 
Biochemical pregnancy (βHCG >10iU/L) was assessed 11 days following embryo transfer and clinical pregnancy assessed at 6 weeks gestation. 
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Daily subcutaneous GnRH antagonist injections (Cetrotide 0·25mg, Merck Serono, injected at 9pm) were commenced from day 5 of rFSH injections until 24 hours prior to kisspeptin trigger injection. If serum LH was undetectable (<0·5 iU/L) on Day 7 of rFSH injections, then the dose of cetrotide was halved to 0·125mg. When at least three ovarian follicles  reached a mean diameter of ≥18mm on ultrasound scan, all patients received a subcutaneous bolus injection of kisspeptin administered by a study investigator to trigger oocyte maturation at 36hrs prior to oocyte retrieval. The dose of kisspeptin was weight-adjusted (9.6nmol/kg), and injection volumes ranged from a minimum of 300µl to 580µl. Patients were then randomised to receive either a second dose of kisspeptin (9.6nmol/kg), or saline placebo injection at 10 hours following the first kisspeptin trigger injection. Patients, IVF physicians and embryologists were blinded to the randomisation. Serum reproductive hormones (LH, FSH, oestradiol and progesterone) were measured immediately prior to, as well as at 4, 10,14 and 20 hours following the first kisspeptin injection.  Transvaginal ultrasound-guided oocyte retrieval (TVOR) was carried out 36 hours following kisspeptin administration under intravenous propofol sedation.  ICSI was performed in all study cycles using sperm from the male partner to allow for stripping of the cumulus oophorus and assessment of oocyte maturation.  All oocytes were fertilised using ICSI as couples with male factor infertility were included in the study.   Definitions of clinical outcomes reported include fertilisation rate (percentage of mature oocytes which fertilised to form two pronuclear (2PN) zygotes following 
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ICSI, embryo formation and quality, biochemical pregnancy rate (serum βhCG >10iU/L 11days after embryo transfer) and clinical pregnancy rate (intrauterine gestational sac with fetal heart pulsation on ultrasound at 6 weeks gestation).  
Embryo Grading: All embryos were assessed on day 3 post TVOR by an embryologist, using the British Fertility Society (BFS) and Association of Clinical Embryologist (ACE) embryo grading scheme for cleavage stage embryos. They describe embryos based on cell number, blastomere size and fragmentation (Table 1). If at day 3 at least 2 embryos had 6 or more cells, <20% difference in blastomere diameter and <20% fragmentation, they were cultured to day 5 post oocyte retrieval in order that the strongest embryos could be identified for transfer. On Day 5, embryos were graded for blastocyst expansion (1 to 6), inner cell mass (A to E) and trophectoderm (A to C). At the blastocyst stage, embryos which scored at least 3 for blastocyst expansion and A or B for inner cell mass and trophectoderm were classified as 
‘high quality embryos’.   
Assessment of Ovarian Hyperstimulation Syndrome (OHSS):  Participants were screened for OHSS by symptoms (abdominal pain and bloating, nausea, vomiting, diarrhoea and subjective reduction in urine output), blood analysis (haemoglobin, haematocrit, white cell count, liver function, renal function, coagulation profile) and ultrasound parameters (ovarian size, presence of ascites in the Pouch of Douglas, adnexae, abdomen or pleural cavity). Women who did not have fresh embryo transfer due to lack of oocyte maturation or failed fertilisation were screened by symptoms alone due to the subsequent low risk of OHSS. For all 
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patients with ≥18 follicles ≥11mm in mean diameter, or serum oestradiol level 
 18,000pmol/L (ie high risk of OHSS), the clinical decision with regards to safety as to whether to proceed with fresh embryo transfer, or to cryopreserve all embryos and conduct embryo transfer in a subsequent cycle (segmentation), was requested from the senior IVF study clinician (G.T.) prior to kisspeptin trigger administration. Women who had segmentation were screened for early OHSS at 5 days following oocyte retrieval, but were only screened for late OHSS by symptoms alone unless the results of early OHSS screening were abnormal. 
OHSS was graded according to RCOG classification (183, 184). The severity of OHSS was independently graded by two experienced IVF clinicians external to the study team (S.L. and R.S.), who were provided with blinded data concerning patient symptoms, blood analysis and ultrasound parameters. In the event of any discrepancy in the categorisation of OHSS, the more severe classification was reported. 
Hormonal assay methodology: 
 Serum LH, FSH, oestradiol, and progesterone were measured using automated chemiluminescent immunoassays (Abbott Diagnostics, Maidenhead, UK). Interassay coefficients of variation were as follows: LH, 3.4%; FSH, 3.5%; oestradiol, 3.4%; progesterone, 1.8%.  Limits of detectability for each assay were as follows: LH 0.07mIU/ml; FSH 0.05mIU/ml; oestradiol 70pmol/l (19pg/mL); progesterone 0.3nmol/L (0.1ng/mL).   AMH was measured using an electrochemiluminescence immunoassay (Roche Cobas e411 assay, Switzerland). The analytical range of detection was 0.01–23 
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ng/ml (0.071-164.2 pmol/L). The lower limit of detection is 0.01 ng/ml (0.071 pmol/L) and the limit of quantitation = 0.030 ng/mL. The interassay coefficient of variance is between 2.9% and 4.4%: 4.4% at 0.232ng/ml (1.66 pmol/L) and 3.8% at the higher end of 18.8ng/ml (134.23 pmol/L). The intraassay coefficient of variance is between 1.1% and 1.8%: 1.8% at 0.232ng/ml (1.66 pmol/L) and 1.5% at the higher end of 18.8ng/ml (134.23 pmol/L). 
Statistical analysis:  The study data were summarised using standard descriptive methods with mean (SD) presented for parametric variables and median (interquartile range) for non-parametric variables. Data analysis was performed by L.H., the study statistician, who had no involvement in patient management or data collection. The primary outcome (proportion of patients achieving an oocyte yield   60%) was compared between treatment groups using a logistic regression model. From the model, an estimate of the difference in success rates and an estimate of the odds ratio for success were derived, together with a p-value and 95% confidence intervals, comparing the two treatment groups. Similar models and analyses were performed for the other binary outcomes: clinical pregnancy rate and implantation rate. Relevant baseline co-variables were tested in all of these models, but none were statistically significant, and so were excluded from these models for derivation of the final results. 
Linear logistic regression models with a gamma error distribution were used to analyse the continuous secondary outcomes (LH, FSH, oestradiol, progesterone levels; mean volume and maximum diameter of ovaries), since exploratory 
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analyses suggested that the data was not normally distributed. These linear models are exactly analogous to conventional analysis of variance/covariance models, but do not assume normal distributions for the outcomes. Estimates of the difference in response between treatment groups, together with 95% confidence intervals and p-values, were derived from each of these models. Relevant baseline co-variables were again tested in all these models. The only co-variables that were statistically significant were the pre-trigger values for the LH, FSH, oestradiol and progesterone fold-change analyses. The results from these models are therefore adjusted for the relevant pre-trigger values. For the analysis of mean volume and maximum diameter of ovaries, no co-variables were statistically significant in exploratory analyses and so were excluded from these models for derivation of the final results. 
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Results: 
Baseline characteristics:  No statistically significant differences in baseline characteristics were identified between the dose groups (Table 4).  
Primary outcome 
Oocyte maturation 
 The study was designed to assess if oocyte maturation can be improved in women having IVF treatment following 2 doses of kisspeptin-54 administration.  The 
proportion of patients achieving an optimal oocyte yield (≥60%) was improved from 45.2% in the single kisspeptin group to 71.0% in the double kisspeptin group (P<0.042). The absolute risk difference in the proportion of patients achieving a satisfactory oocyte yield between the single and double groups was 25.8% (CI 2.1%-49.5%). The odds of achieving an optimal oocyte yield in the double group was increased 2.97-fold (CI 1.04- 8.48). 
Oocyte maturation was observed in the majority of patients following kisspeptin trigger (61/62; 98.4%): (30/31; 96.8%) in the single group and all patients in the double group (31/31; 100%) had at least one mature oocyte retrieved and fertilised to form an embryo. In the single group 3 out of 31 (9.7%) patients had less than 4 oocytes collected. However, no patients in the double dose group had less than 4 oocytes retrieved (see Table 5 for details of oocyte maturation by kisspeptin dosing group and Figure 11 for histogram of number of oocytes retrieved by kisspeptin dosing group).  
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Table 4: Baseline characteristics of patients who received kisspeptin-54 trigger. Contains medians 
(lower quartile, upper quartile) for continuous variables and numbers of patients (percentages) for 
categorical variables. 
* AMH = serum anti-Müllerian hormone in pmol/L 
 
 
 
 
 
 
 Single Double Both 
N 31 31 62 
Age 31.2 ((27.9,33.4) 30.9(29.1,32.6) 31.1(29,32.7) 
Weight(kg) 61.6(58.4,68.2) 68.1(57.4,76.1) 64.5(58.4,73) 
Body mass index 
(kg/m2) 
23.9(21.9,27.2) 26.6(22.8,28.9) 25.5(22.7,28) 
Antral Follicle Count 39(30,52) 33(29,40 36(29,48) 
AMH* (pmol/L) 52.4(36,81.4) 44(34.6,56.4) 45.7(36,63.5) 
Cause of 
infertility 
   
PCOS 17 (54.8%) 18 (58.1%) 35 (56.5%) 
Tubal 1 (3.2%) 0 (0%) 1 (1.6%) 
Male 4 (13%) 2 (7%) 6 (9.7%) 
Mixed 1 (3.2%) 1 (3.2%) 2 (3.2%) 
Unexplained 8 (26%) 10 (32.3%) 18 (29%) 
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 Single (n=31) 
(CI) 
Double (n=31) 
(CI) 
AD (CI, P 
value) 
Both (n=62) 
(CI) 
Primary outcome:                                                     
No. of patients 
achieving                                            
≥60% oocyte yield 
(%) 
14 (45.2%) 22 (71.0%) 25.8%           (2.1%, 
49.5%, P=0.042) 
36 (58.1%) 
Number of Oocytes 12 (7, 18) 13 (10, 17)  12 (8, 17) 
Oocyte Maturation 
Rate (%) 
83.0%                         
(67.0%, 92.0%) 
80.0%                         
(67.0%, 92.0%) 
 82.0%                
(67.0%, 92.0%) 
Oocyte Yield* (%) 52.9%                      
(25.0%, 75.0%) 
63.6%               
(40.0%, 75.0%) 
 58.1%              
(37.5%, 75.0%) 
Number of patients 
with                                                     
≥4 eggs collected 
(%) 
28                          
(90.3%)
31                         
(100%) 
 59                      
(95.2%) 
Fertilisation rate 
(%) 
78.9%            
(55.6%, 83.3%) 
78.6%                 
(66.7%, 92.9%) 
 78.6%            
(64.2%, 88.9%) 
No. of patients with 
at least one 2PN) 
zygote 
30 (96.8%) 31 (100%)  61 (98.4%) 
No. of cleaved 
embryos                                 
at day 3 post ICSI 
6 (3, 9) 8 (5, 10)  7 (4,10) 
Number of embryos                                               
at day 3 graded as 
≥623 (high grade) 
6 (3, 8) 6 (3, 9)  6 (3,9) 
Number of patients                                               
with embryo 
transfer 
29 (93.5%) 31 (100%)  60 (96.8%) 
Number of Embryos 
at day 5 
6 (3, 9) 6 (4, 9)  6 (3, 9) 
Number of High 
quality                             
blastocysts (≥3A/B) 
at day 5 
1 (0, 2) 1 (0, 3)  1 (0, 3) 
Number of patients                                                
with day 5 embryo 
transfer 
26 (83.9%) 29 (93.5%)  55 (88.7%) 
Number of patients 
with transfer of                       
high quality embryo 
at day 5 
 
17 (54.8%) 17 (54.8%)  34 (54.8%) 
Number of patients 
with segmentation 
1 (3.2%) 0 (0.0%)  1 (1.6%) 
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Biochemical 
Pregnancy                                              
rate per protocol 
(%) 
10 (32.3%) 16 (51.6%)  26 (41.9%) 
Clinical Pregnancy                                                   
rate per protocol 
(%) 
7 (23.0%) 12 (39.0%) 16.0                        
(-0.08, 0.38,  P = 
0.199) 
19 (30.6%) 
Implantation Rate                                                    
(SD) 
23.3% (43.0) 37.0% (48.2)  30.3% (45.9) 
Live Birth Rate per 
protocol (%) 
6 (19·4%) 
 
12 (39%) 
 
 18 (29%) 
 
Table 5: Primary and secondary outcomes with clinical outcomes for IVF following kisspeptin-54 
trigger. Contains medians (interquartile range) for continuous variables and totals (percentages of N) for 
categorical variables, AD = Absolute Difference (CI=Confidence Interval).   
Primary Outcome: proportion of patients achieving satisfactory oocyte maturation; defined as the 
proportion of patients achieving an oocyte yield ≥ 60%.  
Secondary Outcomes: Implantation rate, occurrence of OHSS, and reproductive hormone levels.  
Statistical comparison was only performed on the primary and secondary outcomes.   
Oocyte Maturation Rate is the percentage of oocytes collected which were mature.  
Oocyte Yield is the percentage of mature oocytes collected from the number of follicles ≥14mm in 
diameter on the final ultrasound scan prior to kisspeptin-54 trigger administration.  
Fertilisation rate is the percentage of mature oocytes which fertilised to form 2PN zygotes following 
intracytoplasmic injection with sperm (ICSI).  
Implantation rate is defined as the percentage of embryos transferred which implant on assessment by 
ultrasound at 6 weeks of gestation. 
Biochemical Pregnancy rate is defined as serum βhCG >10iU/L 11days after embryo transfer 
Clinical pregnancy rate is defined as intrauterine gestational sac with fetal heart pulsation on ultrasound 
at 6weeks gestation 
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Figure 11: Histogram showing the number of oocytes retrieved by kisspeptin dose group (single administration of kisspeptin or two doses of kisspeptin).  
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Secondary outcomes: 
(i) Reproductive Hormone Levels: 
 Injection with kisspeptin led to a similar rise in LH and FSH between the single and double dose groups. Patients receiving kisspeptin as their second injection (double group) had significantly higher serum LH and FSH levels at 4 hours and 10 hours after the second injection, when compared to those receiving saline as their second injection (single group). The mean change in serum LH was increased 3.3-fold in single group and 14.7-fold in double group at 4hrs following the second injection when compared with pre-trigger levels;( P<0.0001; see Figure 12 for serum hormonal profiles by kisspeptin dosing group). 
For those patients randomised to receive a double dose of kisspeptin, those with a lower serum LH-rise following the first dose of kisspeptin had a more pronounced LH-response following the second dose of kisspeptin (see Figure 13 for bar-chart of change in serum LH at 4hrs following the second dose of kisspeptin by levels of serum LH just prior to administration of the second dose of kisspeptin). However, this did not reach statistical significance.  
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Figure 12: Levels of serum FSH,LH, oestradiol and progesterone (Mean ± SD) after administration of single and double dose kisspeptin at 9.6 nmol/kg at 4, 10, 14 and 20 hours after  1st kisspeptin dose; n=31 per dose 
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Figure 13: Change in serum LH following the second dose in patients randomized to double dose of kisspeptin (KP). Median (IQR) change in serum LH from just prior to the second dose of kisspeptin to 4 h thereafter is shown for patients randomized to two doses of kisspeptin (double; n = 31) by categories of serum LH just prior to the second kisspeptin dose being administered. A greater subsequent response to the second dose of kisspeptin is observed in patients with a lower serum LH just prior to its administration.  
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(ii) Rates of OHSS:  
 The incidence of OHSS did not vary between those who received a single or double dose of kisspeptin (Table 6). Only one woman from sixty-two at high risk of OHSS (1.6%) was diagnosed with moderate early OHSS. She was admitted for analgesia for less than 24hrs on the day following oocyte retrieval and although no medical intervention was required, she was treated with segmentation to safeguard her well-being. No patients were diagnosed with mild early OHSS but one patient in the double group was diagnosed with mild late OHSS (1.6%). 
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OHSS Screening Early   Late   
 Single Double Both 
AD 
(CI) 
P value 
Single Double Both 
AD 
(CI) 
P value 
OHSS Symptoms         
Number of patients screened 
by OHSS symptoms (%) 
31 
(100%) 
31 
(100%) 
62 
(100%)  
31 
(100%) 
31 
(100%) 
62 
(100%)  
Number of patients with 
 1 symptom potentially 
consistent with OHSS (%) 
9 
(29.0%) 
7 
(22.6%) 
16 
(25.8%)  
9 
(29.0%) 
9     
(29.0%) 
18   
(29.0%)  
Number of patients requiring 
medical intervention for 
OHSS (%) 
0 
(0.0%) 
0 
(0.0%) 
0 
0.0%)  
0 
(0.0%) 
0 
(0.0%) 
0 
(0.0%)  
Number of patients requiring 
hospital admission for OHSS 
(%) 
1 
(3.2%) 
0 
(0.0%) 
1 
(1.6%)  
0 
(0.0%) 
0 
(0.0%) 
0 
(0.0%)  
         
Sonographic Screening         
Number of patients screened 
with pelvic ultrasound (%) 
31    
(100%) 
30   
(96.8%) 
61 
(98.4%)  
30    
(96.8%) 
31    
(100%) 
61   
(98.4%)  
Mean ovarian volume           in 
mls (SD) 68.6  (52.1) 
48.2   
(28.9) 
58.6   
(43.2) 
-20.4 
(-39.3, -1.5) 
P = 0.034 
28.9   (40.9) 16.1   (15.9) 22.4 (31.3) 
-12.8 
(-22.5, -3.3) 
P = 0.006 
Mean ovarian diameter         
in mm (SD) 41.5  (10.1) 
38.7     
(7.9) 
40.2 
(9.1)  
29.6 
(9.9) 
25.9      
(6.0) 
27.8 
(8.3)  
Maximal ovarian diameter     
in mm (SD) 64.2  (15.1) 58.1  (11.0) 61.3  (13.6) 
-6.1  
(-12.9, 0.60) 
P = 0.079 
44.7   (14.0) 42.4     (9.5) 43.5 (11.9) 
-2.3 
(-7.7, 3.1) 
P =  0.410 
Number of patients with 
maximum ovarian diameter 
 5cm (%) 
24      
(77.4%) 
22   
(73.3%) 
46   
(75.4%)  
7 
(23.3%) 
7      
(22.6%) 
14 
(23.0%)  
Number of patients with 
maximum ovarian diameter 
 8cm (%) 
5 
(16.1%) 
1 
(3.3%) 
6 
(9.8%)  
1 
(3.3%) 
0 
(0.0%) 
1 
(1.6%)  
Number of patients with 
maximum ovarian diameter 
 12cm (%) 
0 
(0.0%) 
0 
(0.0%) 
0 
(0.0%)  
0 
(0.0%) 
0 
(0.0%) 
0 
(0.0%)  
Total free fluid in abdomen, 
POD / Adnexa in mls (SD) 
5.8       
(8.1) 
3.4 
(5.8) 
4.6 
(7.1)  
3.0      
(11.8) 
0.8        
(2.3) 
1.9 
(8.4)  
Number of patients with 
 grade 2 ascites (%) 
0 
(0.0%) 
0 
(0.0%) 
0 
(0.0%)  
0 
(0.0%) 
0 
(0.0%) 
0 
(0.0%)  
Number of patients with 
pleural effusion (%) 
0 
(0.0%) 
0 
(0.0%) 
0 
(0.0%)  
0 
(0.0%) 
0 
(0.0%) 
0 
(0.0%)  
         
Blood parameters         
Number of patients screened 
with Blood analysis                
31    
(100%) 
29 
(93.5%) 
60 
(96.8%)  
30    
(96.8%) 
31    
(100%) 
61    
(98.4%)  
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Table 6:  Early OHSS screening (3-5days following oocyte retrieval) and late OHSS screening 
(11days following embryo transfer). Assessment for OHSS included symptomatic, sonographic and 
biochemical evaluation. Blinded data evaluation was independently graded by two experienced IVF 
clinicians external to the study team (S.L. and R.S.), according to the RCOG classification of OHSS. 
In the event of any discrepancy in categorisation of OHSS, the more severe classification was 
reported. 
AD = Absolute Difference (CI=Confidence Interval). Mean (SD) is presented for continuous variables and 
number of patients (%) for categorical variables.  
POD, Pouch of Douglas; ALT, Alanine transaminase; AST, Aspartate transaminase; ULN, Upper Limit of 
Normal. 
 
 
 
 
 
(%) 
Number of patients with 
Haematocrit >45%                  
(%) 
0 
(0.0%) 
0 
(0.0%) 
0 
(0.0%)  
0 
(0.0%) 
0 
(0.0%) 
0 
(0.0%)  
Number of patients with 
serum sodium 132mmol/L  
0 
(0.0%) 
0 
(0.0%) 
0 
(0.0%)  
0 
(0.0%) 
0 
(0.0%) 
0 
(0.0%)  
Number of patients with 
Number of patients with 
serum potassium 
 5.0mmol/L                            
(%) 
0 
(0.0%) 
0 
(0.0%) 
0 
(0.0%)  
0 
(0.0%) 
0 
(0.0%) 
0 
(0.0%)  
Number of patients             
with ALT 2xULN                
(%) 
3       
(9.7%) 
1       
(3.4%) 
4 
(6.7%)  
1 
(3.3%) 
1 
(3.2%) 
2 
(3.4%)  
Number of patients           with 
AST 2xULN                   (%) 
2      
(6.5%) 
1 
(3.4%) 
3 
(5.0%)  
0 
(0.0%) 
0 
(0.0%) 
0 
(0.0%)  
Number of patients with total 
protein 80 g/L                      
(%) 
1      
(3.2%) 
0 
(0.0%) 
1 
(1.7%)  
0 
(0.0%) 
0 
(0.0%) 
0 
(0.0%)  
Number of patient with 
creatinine 110 µmol/L (%) 
0  
(0.0%) 
0 
(0.0%) 
0 
(0.0%)  
1  
(3.3%) 
0 
(0.0%) 
1 
(1.6%)  
         
 Number of patients diagnosed with OHSS      
Normal 30  (96.8%) 
31  
(100%) 
61  
(98.4%)  
31  
(100%) 
30  
(96.8%) 
61 
 (98.4%)  
Mild 0 0 0  0 1 (3.2%) 1 (1.6%)  
Moderate 1 (3.2%) 0 1 (1.6%)  0 0 0  
Severe 0 0 0  0 0 0  
Critical 0 0 0  0 0 0  
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(iii) Implantation rate:  A higher implantation rate was observed following a double dose of kisspeptin (37.1%) when compared to a single dose (23.3%) (OR 2.1; CI 0.68-6.3), but this was not statistical significant. The live birth rate was 19·4% in the single group and 39% in the double group 
 
Adverse events  
The administration of kisspeptin-54 was tolerated well in all patients included in this study. This finding is in keeping with the safety profile reported in previous human studies (151, 170, 171, 173, 185). One woman in the single dose group had an unexplained second trimester miscarriage at 19 weeks of gestation.  
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Discussion 
Kisspeptin signaling is essential for mammalian fertility (145, 186) and exogenous administration of kisspeptin can potently stimulate the release of endogenous reproductive hormones in the mammalian species studied (see chapter 1). A single injection of kisspeptin has been shown to result in an LH surge of ~12-14hrs duration that was sufficient to safely trigger oocyte maturation in women at high risk of OHSS and subsequently result in fertilisation, implantation of the embryo and, most importantly, result in live births for infertile women undergoing IVF treatment (181).  
The primary objective of this study was to assess if oocyte maturation can be improved in women having IVF treatment following 2 doses of kisspeptin-54 administration without increasing the incidence of OHSS. In order to investigate the safety and efficacy of kisspeptin in women at high risk of developing OHSS, the inclusion criteria for this trial were a high serum AMH ≥40pmol/L or AFC ≥23. The women in this study had a mean AFC of 40 and mean serum AMH of 52pmol/L confirming successful recruitment of women at high risk of developing OHSS during IVF treatment (96, 180).   
It is reasonable to assume that prolonging the duration of the LH-surge with a second dose of kisspeptin could potentially increase the risk of developing OHSS in the high-risk patient. Such reports have been described in the literature following GnRH-a triggering (187-189).   
This study shows that patients who received two doses of kisspeptin to trigger oocyte maturation had an increased duration of LH and FSH exposure compared to 
90 
 
patients receiving a single dose, leading to an increased proportion of patients achieving an optimal oocyte yield. Oocyte maturation was assessed in two ways: the absolute number of mature oocytes; and the proportion of collected oocytes that were mature (metaphase II).  
The hormonal profiles of patients receiving a second dose of kisspeptin were variable with regards to their LH-response following the second dose of kisspeptin. The response appeared to be dependent on the LH-rise following the first injection of kisspeptin. Patients with a more robust LH-rise following the first dose of kisspeptin had a lower secondary rise following the further dose of kisspeptin. Conversely, those patients with a lower initial LH-response following the first dose of kisspeptin responded with a more potent LH-rise following the second dose of kisspeptin. Therefore, the second ‘rescue’ dose of kisspeptin was able to eliminate the retrieval of fewer than 4 oocytes from 9.7% in the single group to 0% in the double group. 
There are a number of plausible hypotheses as to the variable response that was observed; kisspeptin pharmacodynamics may be explained by its unique mechanism of action. Kisspeptin acts at the level of the hypothalamus to cause the release of a pre-formed endogenous pool of GnRH (190). Patients with a greater LH-rise following the first dose of kisspeptin may have depleted their hypothalamic GnRH reserves to the extent that a second injection of kisspeptin only resulted in a modest further LH-response of what remained. Whereas patients with a lower rise in LH following the first dose of kisspeptin may have a greater residual hypothalamic GnRH store, allowing a second dose of kisspeptin to induce a larger LH-response.  
91 
 
Another possibility is that the variability in LH-response is a result of tachyphylaxis at the kisspeptin receptor. This hypothesis, however, seems less likely as tachyphylaxis is more usually associated with high-dose and frequent administrations of kisspeptin rather than two intermediate doses administered 10 hours apart, as in this study (191).  
Kisspeptin’s ability to stimulate gonadotrophin secretion based on patient’s individually determined endogenous GnRH reserve, without causing excessive response, is of key significance in women undergoing IVF treatment at high risk of developing OHSS. Despite the study population recruited being at high risk of developing OHSS, a second dose of kisspeptin did not increase the proportion of patients developing OHSS.  
There is data to suggest that kisspeptin may reduce the incidence of OHSS via alternative factors other than its shorter duration of action. Firstly, kisspeptin has been shown to inhibit the production of VEGF, one of the main angiogenic cytokines implicated in the pathophysiology of OHSS, in studies conducted looking at tumour angiogenesis (192). Moreover, kisspeptin acts via the release of a preformed endogenous pool of GnRH from the hypothalamus rather than a pharmacological dose of GnRH (171, 190). Therefore, as the quantity of endogenous GnRH is individually determined and tailored to each patient, kisspeptin is less likely to produce an excessive ovarian response (181).  
Although 48% (30/62) of patients in the trial had more than 25 follicles ≥11mm mean diameter on the day of trigger, the majority of patients (98.4%; 61/62) were still able to safely proceed with a fresh embryo transfer following kisspeptin triggering. Only one participant did not have a fresh embryo transfer: she had an 
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AFC of 84 and a serum AMH of 165pmol/L. This patient developed 73 follicles 
≥11mm on the morning of trigger and her serum oestradiol was 38,264pmol/L. At collection 46 oocytes were retrieved, of which 41 were mature. The day following oocyte retrieval, she developed abdominal pain and was admitted for analgesia for a period of less than 24hrs before her symptom resolved spontaneously. At screening for early OHSS, her maximal ovarian diameter was 10cm, she had no biochemical abnormalities suggestive of OHSS and the total amount of ascites was 50mls. She was graded as moderate OHSS by one reviewer and as mild OHSS by the other.  
Of important note, prospective clinical trials in which routine screening for OHSS is conducted an increased frequency of OHSS is often reported when compared with retrospective trials in which symptom-prompted, rather than universal, screening of OHSS is conducted (193, 194). It is therefore reassuring still that despite routine screening of women at high risk of OHSS, two doses of kisspeptin can be safely administered without causing an increased risk of ovarian hyper-response and OHSS. 
Some researchers have proposed that all women with 25 or more follicles ≥11mm, or those considered high risk of OHSS should freeze all their embryos and segment their cycle in order to avoid late-onset OHSS (195, 196). However, a universal segmentation policy may result in increased cost of treatment and increased time to pregnancy when compared to fresh embryo transfer, which is not often a favoured option by patients.  
The clinical pregnancy rate in this trial was comparable to that observed following hCG-triggering in clinical trials (194). Thus, using kisspeptin to trigger oocyte 
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maturation could provide a useful clinical option to all women, especially those at high risk of OHSS, to enable fresh embryo transfer without compromising patient safety or pregnancy rates. 
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Conclusion and future work: 
A second dose of kisspeptin administered 10 hours following the first can improve the proportion of patients achieving optimal oocyte maturation, but without increasing the risk of OHSS. Therefore, a second dose of kisspeptin is a safe option in patients undergoing IVF treatment to further optimise oocyte yield, even those at high risk of OHSS. 
The detailed analysis of the FSH, LH, oestradiol and progesterone levels during ovarian stimulation and the luteal phase will allow us to gain further insight into the reproductive hormonal milieu prior to and after the administration of kisspeptin. Future prospective studies are needed to  directly compare kisspeptin and other triggers of oocyte maturation currently used in clinical practice: namely hCG and GnRH agonist, to adequately assess the clinical and live birth rates in particular as well as the incidence and severity of OHSS.  
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Chapter 3 
Assessment of OHSS 
following ovarian 
stimulation with 
different triggers of 
oocyte maturation: 
kisspeptin, GnRH agonist 
and hCG 
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Introduction 
OHSS is the main complication of IVF treatment. Several classifications have been proposed based on symptoms, ultrasound findings and laboratory parameters (Table 7). Historically, OHSS has been graded as mild, moderate, severe or critical (183, 184). Further objective assessments including ovarian volume were used in a recent RCT to compare the risk of severe OHSS between GnRH agonist versus antagonist in 1,050 IVF cycles (194). 
However, there has been no clear consensus between investigators regarding a standardised classification for OHSS. In addition, there is a distinct lack of normative data for ovarian volume following ovarian stimulation (this criteria is present in the RCOG Greentop Guideline for the management of OHSS and in the Golan classification). Some degree of ovarian hyperstimulation is expected with the use of follicular stimulants, but the point at which symptoms transition from being anticipated effects to those indicative of pathology remain unclear. There has, however, been a recent review published to grade OHSS in the clinical trial setting (199). With regards to laboratory parameters, again, situation appropriate, standardised, normal ranges for women undergoing ovarian stimulation are lacking. Indeed, elevated liver enzymes in a woman with moderate OHSS have been reported (200). In addition the clinical significance of some of these parameters, such elevated liver enzymes, have not been established.  
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Table 7: Classification of OHSS including symptoms, ultrasound and haematological markers 
(Golan et al., 1989, Navot et al., 1992) 
 
 
 
 
 
 
 
 
 
       Mild OHSS   Grade 1: Abdominal distension and discomfort, nausea, vomiting and enlarged ovaries- defined as >80mm  
       Moderate OHSS   Mild OHSS with ultrasonic evidence of pelvic or abdominal ascites 
        Severe OHSS   Moderate OHSS with clinical evidence of ascites and/or hydrothorax 
       Critical OHSS  Severe OHSS with oliguria and renal failure, thromboembolism or adult respiratory distress syndrome and abnormal laboratory parameters: haematocrit >45%; (ii) creatinine > 90 µmol/l; (iii) alanine aminotransferase (ALT) >45 U/l.  
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Risk factors 
 Certain patient and cycle characteristics increase the risk of OHSS; women with a previous history of OHSS, polycystic ovary syndrome (94), increased antral follicle 
count (AFC) ≥ 23 or high levels of anti-Mu llerian hormone (AMH) (95, 96), low body mass index (BMI) (97), young age (94), elevated serum oestradiol during ovarian stimulation (98) and high doses of exogenous FSH during ovarian stimulation (99). The risk of OHSS is also related to the number of developing follicles >15 follicles over 15mm in size on the day of trigger (42, 100) and the number of retrieved oocytes at the end of the cycle (43). 
Pathophysiology OHSS can also be classified as early or late onset. The cause of early onset OHSS is typically due to the use hCG to induce oocyte maturation prior to retrieval. Late OHSS is induced by endogenous hCG from pregnancy and is observed after more than 10 days post oocyte retrieval. Although hCG and luteinising hormone (LH) share the same alpha subunit, the circulating half-life of hCG is much longer than that of LH; circulating for up to 7 days post administration (31) compared to the physiological LH surge lasting approximately 48 hours (102). As a consequence hCG binds to LH receptors in the corpora lutea for longer which can excessively stimulate the ovary, driving the pathophysiology of this condition.  
VEGF has emerged as one of the factors most likely involved in the pathophysiology of OHSS (105). VEGF is an angiogenic cytokine that is a potent stimulator of the vascular endothelium and appears to play an integral role in follicular growth, 
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corpus luteum function, and ovarian angiogenesis. Recent studies also indicate that hCG increases VEGF expression in human granulosa cells and raises serum VEGF concentrations (106, 107). VEGF has been implicated as it known to increase vascular permeability to high molecular weight proteins promoting capillary leakage (108). As such there is a clinical need to improve IVF protocols to eliminate the occurrence of OHSS. Since triggering oocyte maturation with hCG is a major cause of OHSS, newer triggers such as GnRHa and kisspeptin have been investigated as potentially safer triggers.  
Triggering of oocyte maturation 
hCG : Ovulation in a natural cycle is initiated and perpetuated by a mid-cycle surge of LH released by the pituitary gland. The LH surge acts to induce final oocyte maturation whereby the first meiotic division is completed with extrusion of the polar body and it is then arrested in prophase of the second meiotic division until fertilisation.  hCG shares the same alpha subunit and 81% of the amino acids of the beta subunit of LH and hence binds to the same receptor (30) hCG also has a stimulating action on the development and function of the corpus luteum; namely a luteotrophic effect, that is more potent owing to its longer half-life compared to the endogenous LH surge and as such hCG can still be detected in the serum 10 days after the preovulatory bolus injection (31). Consequently, continued support of the corpus luteum by hCG elicits supraphysiological luteal phase steroid concentrations. In combination with an exaggerated  ovarian reponse secondary to stimulation (i.e. a large number late follicular phase follicles and very high oestradiol levels), hCG has clearly been associated with an increased risk of OHSS (42-44).  
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GnRH agonist: GnRHa admimistration initially induces a surge in gonadotrophin production 
termed the ‘flare’ effect. With the advent of the GnRH antagonist protocol, where the GnRH receptor competitively inhibited rather than desensitised, a GnRHa can be used as an alternative to hCG to induce oocyte maturation. The GnRHa displaces the GnRH antagonist from the pituitary GnRH receptor, and activates it,  thereby initiating an endogenous surge of gonadotrophins, namely LH and FSH.  
The gonadotrophin surge generated by administration of  GnRHa is shorter than the physiogical LH surge that occurs in a normal menstrual cycle: 24 hours compared to 48 hours respectively (28).  
The shortened duration of the LH surge with a GnRHa trigger significantly reduces the total amount of LH released when compared to a normal menstrual cycle (27, 28). In rodents GnRHa administration is associated with structural luteolysis of the corpora lutea via matrix metalloproteinase activity (201). As a result, the GnRHa trigger has a much better safety profile with regards to OHSS when compared to hCG (48, 49, 202).  
Kisspeptin: Kisspeptin is a hypothalamic peptide, that is encoded by the KiSS1 gene, which is a neuromodulator acting upstream of GnRH. Kisspeptin stimulates GnRH neurons directly through its action on the kisspeptin receptor to release GnRH into the hypothalamo-pituitary portal circulation, which in turn stimulates the secretion of LH and FSH from the gonadotrophs of the anterior pituitary (131, 203). 
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Exogenous administration of kisspeptin has been shown to be able to effectively induce a potent LH surge and subsequent oocyte maturation in women undergoing IVF treatment (179) and also in those at high risk of OHSS (181). In these two studies a single injection of kisspeptin resulted in an LH surge which lasted for 12 hours compared to the 24 hour LH surge with GnRHa as mentioned previously.  
Peak levels of hCG occur at 24 hours post administration (182) whereas with GnRHa (204) and kisspeptin (179) this occurs at 4 hours.  Therefore, the total amount of gonadotrophin released during the duration of the surge is significantly reduced when GnRHa is used and even less so with kisspeptin owing to the shorter duration of the LH surge (12 hours). The resulting lower circulating LH concentrations will promote earlier luteolysis compared to hCG.  
 In another recent study directly comparing equimolar administration of kisspeptin-10 and 54 with GnRH and on gonadotrophin secretion, GnRH was found 
to be more potent than kisspeptin’s indirect hypothalamic stimulation. Therefore, theoretically kisspeptin may have a therapeutic advantage over GnRH in mitigating adverse clinical consequences secondary to excessive gonadotrophin stimulation; namely OHSS (190).  
To determine conclusively the efficacy and safety of hCG vs GnRHa vs kisspeptin in IVF treatment, prospective studies are needed. However, in the absence of these studies, I compared the incidence of OHSS symptoms and ultrasound markers in our IVF unit who had hCG, GnRHa or kisspeptin as their trigger for oocyte maturation in their IVF cycle.  
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Methods 
The inclusion criteria selected women at high risk of OHSS: serum anti-Müllerian 
hormone (AMH) ≥40pmol/L (≥5·6ng/mL) or total antral follicle count (AFC) ≥23; age 18-34yrs; early follicular phase serum follicle stimulating hormone (FSH) 
≤12iU/L; both ovaries intact; body mass index 18-29kg/m2. Women in the kisspeptin group were universally screened sonographically and for symptoms of OHSS 2-5 days following oocyte retrieval) at Hammersmith Hospital, London, UK (2013-2016). Patients in the hCG and GnRHa groups were screened if clinicians deemed them at high risk of developing OHSS or they developed symptoms of OHSS post oocyte retrieval. 
Ovarian volume on ultrasound, ascitic volume and OHSS symptoms were determined when patients were triggered with (hCG) (n=44), GnRH agonist (GnRHa) (n=94) or kisspeptin (n=115) at time of early OHSS screening (2-10 days following oocyte retrieval). In the kisspeptin group data was collected as part of a prospective clinical trial. In the hCG and GnRHa agonist groups, data was collected from matched patients retrospectively that met the inclusion criteria.   
Statistical analysis  The distribution of continuous variables was compared to the normal distribution using the Kolmogorov-Smirnov test. Non-parametrically distributed variables were log transformed to maximise power. The study data were summarised using standard descriptive methods with mean (SD) presented for parametric variables and median (interquartile range) for non-parametric variables. Non- parametrically distributed, continuous variables (mean ovarian volume, change in ovarian volume and mean ascitic volume) were log-transformed prior to analysis 
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to maximise power. Analysis of continuous variables was performed using One-way ANOVA with post-hoc Tukey’s test to examine pairwise differences between the three groups. Analysis of dichotomous variables (presence of individual OHSS symptoms) was performed using the Chi-squared test, with examination of standardised residuals to determine the significance of pairwise differences between the three groups.   
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Results 
Baseline characteristics Two hundred and sixty-one women at high risk of OHSS received either hCG (n=40), GnRHa (n=99), or kisspeptin (n=122) to trigger oocyte maturation. The cohort studied was at high risk of OHSS with a median of 38 antral follicles, 24 
follicles ≥11mm on the day of trigger and 19 oocytes retrieved. There were significant imbalances between the treatment groups as clinicians are more likely to recommend GnRHa trigger rather than hCG trigger for patients deemed at higher risk of OHSS (see Table 8).  
 Average mean ovarian volume (MOV) following hCG trigger was 172mls ±89mls, 88 ±60mls after GnRHa trigger and 53±37mls following kisspeptin trigger (p<0.0001) (see Table 8). The mean change in ovarian volume from baseline to OHSS screening for hCG was 166±87mls (25-fold), 75±56mls (10-fold) with GnRHa and 41±35mls (6-fold) following kisspeptin (p<0.0001) Mean total ascitic volume following hCG, GnRHa and kisspeptin trigger was 92± 131mls, 5.7 ± 21.5mls and 4.8± 7.8mls respectively. These volumes were statistically significant when comparing hCG with kisspeptin and GnRHa (p<0.0001). However these values did not reach statistical significance between kisspeptin and GnRHa (see Figure 13).  
Abdominal pain and bloating were reported in 73% and 84% respectively of patients triggered with hCG, 20% and 28% with GnRHa trigger and 13% and 12% following kisspeptin trigger.  The incidence of bloating was statistically significant between all three groups (p<0.0001). However, abdominal pain was only 
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statistically significant when comparing hCG with kisspeptin or GnRHa (p<0.0001).  Nausea and vomiting occurred in 43% and 9% respectively of patients triggered with hCG, 12% and 4% following GnRHa trigger and 3% and <1% of patients triggered with kisspeptin (p<0.0001). The incidence of nausea was statistically significant between all three groups (p<0.0001). However, vomiting was only statistically significant when comparing hCG with kisspeptin or GnRHa (p<0.05) (see Figure 14). The percentage of patients where >10mls of ascitic fluid was detected upon ultrasound during early OHSS screening following administration of hCG, GnRHa and kisspeptin was 80%, 18% and 16% respectively (p<0.0001)(see Table 10).  
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 hCG GnRHa Kisspeptin All  P value 
N 40 99 122 261 
Age (y)  32·4  (30·0-35·3) 
30·0  
(28·0-33·0) 
31·0  
(29·0-33·0) 
31  
(29-33) 0·013 
Body mass index (kg/m2)  24·6  (21·0-27·0) 
24·7  
(21·0-27·7) 
24·5  
(21·2-27·3) 
24·6  
(21·0-27·3) 0·97 
Antral Follicle Count (AFC)  36  (20-40) 
42  
(33-55) 
36  
(29-49) 
38  
(29-50) 
<0·000
1 
Total recombinant FSH dose 
(IU) 
1781  
(1325-2325) 
1500  
(1113-2025) 
1238  
(1050-1575) 
1350  
(1125-1950) 0·0002 
Mean daily rec FSH dose (IU) 150  (113-225) 
122  
(111-150) 
113  
(112-131) 
119  
(113-150) 
<0·000
1 
Long Protocol (%) 55% 0% 0% 8% <0·0001 
Number of follicles  
on day of trigger 
36  
(32-41) 
40  
(35-48) 
33  
(26-41) 
37  
(29-34) 
<0·000
1 
Number of follicles ≥11mm  
on day of trigger  
23 
(20-31) 
27  
(23-34) 
22  
(15-27) 
24  
(19-30) 
<0·000
1 
Number of follicles ≥14mm 
on day of trigger 
16 
(10-20) 
15  
(13-21) 
13  
(9-17) 
14  
(10-19) 0·001 
Number of oocytes retrieved 21 (17-24) 
27  
(20-34) 
12  
(8-15) 
19  
(12-27) 
<0·000
1 
Mean day of OHSS assessment 
(% between days 3-5  
post oocyte retrieval) 
4·1 
(74%) 
4·1 
(85%) 
4·7 
(99%) 
4·4 
(90%) 
<0·000
1 
% treated with segmentation 51% 13% 8% 17% <0·0001 
 
Table 8:  Baseline characteristics. Median (IQR) is presented for continuous variables and were compared by Kruskal Wallis test. Proportion is presented for binary variables and compared by Chi squared test. Long protocol denotes the use of a GnRH agonist to prevent premature ovulation during controlled ovarian stimulation prior to trigger.  
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Trigger hCG GnRHa Kisspeptin P value 
Mean ovarian 
volume (mls) 
(±SD)  
172±89 88±60 53±37 <0.0001 
Mean ascitic 
volume (mls) 
(±SD) 92± 131 5.7 ± 21.5 4.8± 7.8 <0.0001  
Table 9: Mean ovarian volume and mean ascitic volume ± standard deviation following oocyte maturation triggers hCG, GnRHa and kisspeptin. . Analysis of continuous variables was performed using One-way ANOVA with post-hoc Tukey’s test to examine pairwise differences between the three groups  
Trigger hCG (%) GnRHa (%) Kisspeptin (%) P value 
Nausea 43 12 3 <0.0001 
Vomiting 9 4 <1 <0.05 
Abdominal 
pain 
72 20 13 <0.0001 
Abdominal 
bloating 
84 28 12 <0.0001 
Total ascites 
>10mls 
80 18 16 <0.0001 
 
Table 10: Percentage of patients reporting symptoms of OHSS: nausea, vomiting, abdominal pain and bloating, and the percentage of patients where >10mls of ascitic fluid was detected on ultrasound during early OHSS screening. Analysis of of individual OHSS symptom was performed using the Chi-squared test, with Bonferroni correction to determine the significance of pairwise differences between the three groups 
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Figure 13: Column graphs demonstrating average mean ovarian volume and mean ascitic volume ± standard deviation (mls) following oocyte maturation triggers hCG, GnRHa and kisspeptin                 **** = p<0.0001 
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Figure 14: Column graphs demonstrating the percentage of patients reporting OHSS symptoms by trigger: namely abdominal pain and bloating, nausea and vomiting. 
**** = p<0.0001    * = p<0.05 
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Discussion 
It is well established that after administration of hCG, there is an increased risk of developing OHSS compared to when a GnRHa agonist is used for triggering final oocyte maturation. This is largely owing to the long half-life of hCG and its subsequent potent luteotrophic effect. The excessive stimulation of multiple corpora lutea following oocyte retrieval leads to multiple vasoactive active substances being released by the ovary, altering capillary permeability, leading to the large fluid shifts from the intravascular to the extravascular space which are pathognomonic of OHSS.  
An attractive approach to avoiding OHSS is to substitute hCG. GnRHa have been successfully used in this manner and have led the way thus far in reducing the incidence of OHSS. However, owing to the short half-life of the endogenous LH peak with GnRHa triggering, most of the studies performed in patients showed reduced implantation and pregnancy rates. This results in a need to identify novel oocyte maturation triggers that have an effective safety profile in terms of reducing the risk of OHSS, compared to what is currently available, but that also maintain on-going pregnancy success rates. 
Kisspeptin has been shown to effectively trigger oocyte maturation and phase 2 studies have identified the optimal dosing regimes for improving the oocyte yield (see previous chapter). The rate of OHSS reported in these studies was low and ranged from 1.6-5% (181). However, this study is the first direct comparison between kisspeptin and the other triggers used for final oocyte maturation with regards to assessing symptoms and ultrasonographic markers of OHSS. 
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Mean ovarian volume (MOV) was significantly lower following GnRHa when compared to hCG and was significantly lower still when comparing kisspeptin  to GnRHa (p<0.0001). Compared to baseline ovarian volumes prior to commencing ovarian stimulation, ovarian volumes at early OHSS screening remained enlarged 24-fold following hCG, 10-fold following GnRHa and 6-fold following kisspeptin triggering. This observation could be explained by the reduced total length of the LH surge (12-14 hrs single group; 20 hours in double group) following kisspeptin injection. The reduced kisspeptin-induced LH surge duration and amplitude of the LH peak when compared to GnRHa and hCG results in significantly reduced  total quantity of LH produced. As the corpora lutea are dependent on pituitary LH support, this is likely to be associated with increased luteolysis, structural and functional regression of the corpora lutea and subsequently quicker reduction in ovarian volume following stimulation. Again, the same trend was observed with mean total ascitic volumes, with the lowest volumes being observed in those triggered with kisspeptin followed by GnRHa and the most being reported with hCG.  
Patients reported symptoms of OHSS most frequently following hCG trigger, followed by GnRHa and least of all with kisspeptin across parameters. Abdominal pain was reported in 72% following hCG, 20% following GnRHa and 13% following kisspeptin. Abdominal bloating was reported in 84% following hCG, 28% following GnRHa and 12% following kisspeptin. Nausea was reported in 43% following hCG, 12% following GnRHa and 3% following kisspeptin. Vomiting was reported in 9% following hCG, 4% following GnRHa and <1% following kisspeptin.  
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This data demonstrates a positive correlation between the mean ovarian volume, the ascitic volume and presence of OHSS symptoms. An explanation for this could be that the more active the corpora lutea are, due to more prolonged LH receptor stimulation either via hCG or GnRHa-induced LH, the larger they remain and the more vasoactive substances are released from the ovary. This alters capillary permeability to a greater extent, causing larger fluid shifts and accumulation of fluid in the third space compartment. This, in addition to the mechanical pain or bloating associated with enlarged ovaries, can lead to initiation or exacerbation of OHSS symptoms. The shorter duration of the LH surge observed following kisspeptin is likely to be associated with quicker luteal regression and ovarian recovery back to their physiological state.  
Limitations: 
As in any observational analysis there may be unmeasured confounding, and here particularly a risk of confounding by indication. This study was non-randomised and therefore managing clinicians may have been less likely to assign patients thought to be at high risk of OHSS to an hCG trigger. There is also risk of differential loss to follow up. Patients in the kisspeptin trials were uniformly asked to attend for OHSS screening between days 2-5 following oocyte retrieval, and indeed more than 97.5% had both sonographic and symptom screening. Women assigned to GnRHa or hCG groups were screened between day 2-10 post oocyte retrieval whenever they were considered at substantial risk of OHSS on the day of trigger or if they presented with symptoms.  
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Conclusion and future work: 
This study has shown for the first time, that kisspeptin is associated with a reduced incidence of OHSS symptoms and a quantitative reduction in the ultrasound parameters used to grade the severity of OHSS: namely ovarian size and the ascitic volume. This pilot data lays the foundation for a similar comparison where kisspeptin will be compared to GnRHa and hCG in a prospective, randomised trial as well as analysis of the luteal phase hormonal profile following each trigger.  
Based on the results of this study, kisspeptin has the potential to be the safest trigger for oocyte maturation during IVF treatment.  
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